{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:39:02Z","timestamp":1788863942952,"version":"build-2803163510"},"reference-count":844,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1055\/a-2189-6353","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T20:12:15Z","timestamp":1704831135000},"page":"e67-e161","source":"Crossref","is-referenced-by-count":10,"title":["S3-Leitlinie \u201eDiagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms\u201c \u2013 Langversion 4.0"],"prefix":"10.1055","volume":"62","author":[{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Albert","sequence":"additional","affiliation":[{"name":"Katharinenhospital, Klinik f\u00fcr Allgemeine Innere Medizin, Gastroenterologie, Hepatologie, Infektiologie und Pneumologie, Stuttgart"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bl\u00f6dt","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u200aV.(AWMF), Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Boda-Heggemann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlentherapie und Radioonkologie, Universit\u00e4tsklinikum Mannheim"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brunner","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Strahlentherapie-Radioonkologie, Medizinische Universit\u00e4t Graz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Caspari","sequence":"additional","affiliation":[{"name":"Klinik Niederrhein Erkrankungen des Stoffwechsels der Verdauungsorgane und Tumorerkrankungen, Bad Neuenahr-Ahrweiler"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Toni","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, LMU M\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dombrowski","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4t Greifswald"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Evert","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4t Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Follmann","sequence":"additional","affiliation":[{"name":"Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e.\u200aV., Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Freudenberger","sequence":"additional","affiliation":[{"name":"Clinical Guideline Services GmbH (CGS), Berlin\/Kiel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Gani","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Radioonkologie, Universit\u00e4tsklinikum T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlenheilkunde, Department f\u00fcr Radiologische Diagnostik und Therapie, Universit\u00e4tsklinikum Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"G\u00f6tz","sequence":"additional","affiliation":[{"name":"Medizinische Klinik IV \u2013 Gastroenterologie\/Onkologie, Klinikverbund S\u00fcdwest, B\u00f6blingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Radiologie, Neuroradiologie und minimal invasive Therapie, M\u00fcnchen Klinik Bogenhausen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Thorsten","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institut und Poliklinik f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum Dresden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Huppert","sequence":"additional","affiliation":[{"name":"Radiologisches Zentrum, Max Grundig Klinik, B\u00fchlerh\u00f6he"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krug","sequence":"additional","affiliation":[{"name":"Strahlentherapie Campus Kiel, Universit\u00e4tsklinikum Schleswig-Holstein"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian La","family":"Foug\u00e8re","sequence":"additional","affiliation":[{"name":"Nuklearmedizin und Klinische Molekulare Bildgebung, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Lang","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein-, Viszeral- und Transplantationschirurgie, Johannes Gutenberg-Universit\u00e4t, Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langer","sequence":"additional","affiliation":[{"name":"Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e.\u200aV., Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lenz","sequence":"additional","affiliation":[{"name":"Zentrale Einrichtung Palliativmedizin, Universit\u00e4tsklinikum M\u00fcnster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"L\u00fcdde","sequence":"additional","affiliation":[{"name":"Medizinische Klinik f\u00fcr Gastroenterologie, Hepatologie und Infektiologie, Universit\u00e4tsklinikum D\u00fcsseldorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mahnken","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum Marburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Nadalin","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein-, Viszeral- und Transplantationschirurgie, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Huu Phuc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Humangenetik, Ruhr-Universit\u00e4t, Bochum"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Nothacker","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u200aV.(AWMF), Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Ockenga","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Gesundheit Nord, Klinikverbund Bremen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Oldhafer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Leber-, Gallenwegs- und Pankreaschirurgie, Asklepios Klinik Barmbek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Paprottka","sequence":"additional","affiliation":[{"name":"Sektion f\u00fcr Interventionelle Radiologie, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pereira","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Radiologie, Minimal-invasive Therapien und Nuklearmedizin, SLK-Klinken Heilbronn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Persigehl","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum K\u00f6ln"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Plentz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Gesundheit Nord, Klinikverbund Bremen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Pohl","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Gastroenterologie, Asklepios Klinik Altona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Recken","sequence":"additional","affiliation":[{"name":"Hamburger Fern-Hochschule"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, St\u00e4dtisches Klinikum Karlsruhe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Riemer","sequence":"additional","affiliation":[{"name":"Lebertransplantierte e.\u200aV."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Ritterbusch","sequence":"additional","affiliation":[{"name":"Hospizarbeit am Universit\u00e4tsklinikum Essen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Roeb","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II Pneumologie, Nephrologie und Gastroenterologie, Universit\u00e4tsklinikum Gie\u00dfen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"R\u00fcssel","sequence":"additional","affiliation":[{"name":"Medizinische Klinik IV H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Halle (Saale)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schellhaas","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I Gastroenterologie, Pneumologie und Endokrinologie, Friedrich-Alexander-Universit\u00e4t, Erlangen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[{"name":"Allgemeine Pathologie und pathologische Anatomie, Universit\u00e4tsklinikum Heidelberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00fcrgen","family":"Schlitt","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Chirurgie, Universit\u00e4tsklinikum Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmid","sequence":"additional","affiliation":[{"name":"Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU M\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schuler","sequence":"additional","affiliation":[{"name":"Medizinische Klinik, Gastroenterologie, Alb-Fils-Kliniken, Geislingen an der Steige"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seehofer","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Viszeral-, Transplantations-, Thorax- und Gef\u00e4\u00dfchirurgie, Universit\u00e4tsklinikum Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Sinn","sequence":"additional","affiliation":[{"name":"II. Medizinische Klinik und Poliklinik (Onkologie, H\u00e4matologie, Knochenmarktransplantation mit Abteilung f\u00fcr Pneumologie), Universit\u00e4tsklinikum Hamburg-Eppendorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stengel","sequence":"additional","affiliation":[{"name":"Innere Medizin VI \u2013 Psychosomatische Medizin und Psychotherapie, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Steubesand","sequence":"additional","affiliation":[{"name":"Clinical Guideline Services GmbH (CGS), Berlin\/Kiel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stoll","sequence":"additional","affiliation":[{"name":"Klinik Herzogh\u00f6he Bayreuth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Ruhr-Universit\u00e4t Bochum"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Taubert","sequence":"additional","affiliation":[{"name":"Klinische Sozialarbeit, Universit\u00e4tsklinikum Heidelberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Tholen","sequence":"additional","affiliation":[{"name":"Deutscher Bundesverband f\u00fcr Physiotherapie (ZVK) e.\u200aV."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1: Gastroenterologie und Hepatologie, Pneumologie und Allergologie, Endokrinologie und Diabetologie sowie Ern\u00e4hrungsmedizin, Goethe-Universit\u00e4t, Frankfurt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"van Thiel","sequence":"additional","affiliation":[{"name":"Deutsche Leberhilfe e.\u200aV."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogl","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Goethe-Universit\u00e4t, Frankfurt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wacker","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Waidmann","sequence":"additional","affiliation":[{"name":"Onkologie Bethanien, Frankfurt am Main"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Wege","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemeine Innere Medizin, Onkologie\/H\u00e4matologie, Gastroenterologie und Infektiologie, Klinikum Esslingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Wildner","sequence":"additional","affiliation":[{"name":"Innere Medizin, Krankenh\u00e4user N\u00fcrnberger Land GmbH, Standort Lauf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, H\u00e4matologie und internistische Onkologie und Endokrinologie, Klinikum Dortmund"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galle","sequence":"additional","affiliation":[{"name":"1. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Nephrologie, Rheumatologie, Infektiologie, Johannes Gutenberg-Universit\u00e4t, Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar","family":"Malek","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universit\u00e4t, T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.21176","article-title":"The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients","volume":"43","author":"A Sangiovanni","year":"2006","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"G N Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823?download=true","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"F Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"F Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","article-title":"A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk","volume":"3","author":"C T Frenette","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bpg.2013.08.021","article-title":"Cost-effectiveness of liver cancer screening","volume":"27","author":"A Cucchetti","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jvh.12727?download=true","article-title":"Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score","volume":"24","author":"W P Brouwer","year":"2017","journal-title":"J Viral Hepat"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"G Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"G V Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"M F Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"H I Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"V W Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"72","author":"T C Yip","year":"2020","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913?download=true","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"J A Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease","volume":"14","author":"S Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"173","author":"J Thomas","year":"2022","journal-title":"Eur J Cancer"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2021.08.030","article-title":"An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD","volume":"76","author":"S Loosen","year":"2022","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"L Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1055\/s-0035-1553193","article-title":"[S2k Guideline non-alcoholic fatty liver disease]","volume":"53","author":"E Roeb","year":"2015","journal-title":"Z Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) \u2013 current treatment recommendations and future developments","volume":"57","author":"E Roeb","year":"2019","journal-title":"Z Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496?download=true","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"P Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MCG.0000000000000581","article-title":"Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid","volume":"51","author":"S Tanwar","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"F Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/hep.22870","article-title":"Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography","volume":"49","author":"R Masuzaki","year":"2009","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535?download=true","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"H B El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"G N Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"R Younes","year":"2018","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/CLEP.S144368","article-title":"Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes","volume":"9","author":"J C Simeone","year":"2017","journal-title":"Clin Epidemiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"N Fujiwara","year":"2018","journal-title":"J Hepatol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population","volume":"72","author":"H Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.0954-6820.1984.tb05005.x","article-title":"Hepatocellular carcinoma in patients with acute intermittent porphyria","volume":"215","author":"F Lithner","year":"1984","journal-title":"Acta Med Scand"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/joim.12646","article-title":"Acute hepatic porphyria and cancer risk: a nationwide cohort study","volume":"282","author":"C Baravelli","year":"2017","journal-title":"J Intern Med"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3346\/jkms.2020.35.e5","article-title":"Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study","volume":"35","author":"H Jang","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"S 01","key":"ref39","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/BF02072092","article-title":"Glycogen storage disease I and hepatocellular tumours","volume":"152","author":"L Bianchi","year":"1993","journal-title":"Eur J Pediatr"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"M de Fost","journal-title":"Blood Cells Mol Dis"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: an international case series","volume":"41","author":"M Regenboog","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-014-9683-x","article-title":"Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function","volume":"37","author":"D Bartlett","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/liv.13142?download=true","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"E Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"G V Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study","volume":"42","author":"K Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Liver Int"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(09)70241-4","article-title":"Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"D Poon","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199706263362602?articleTools=true","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children Taiwan Childhood Hepatoma Study Group","volume":"336","author":"M H Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"G Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/dji040","article-title":"Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan","volume":"97","author":"M Inoue","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies","volume":"26","author":"F Bravi","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3945\/ajcn.115.116095","article-title":"The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition","volume":"102","author":"K Aleksandrova","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2014.10.005","article-title":"Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort","volume":"148","author":"V W Setiawan","year":"2015","journal-title":"Gastroenterology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/liv.12304","article-title":"Impact of coffee on liver diseases: a systematic review","volume":"34","author":"S Saab","year":"2014","journal-title":"Liver Int"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.15403\/jgld-805","article-title":"Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis","volume":"29","author":"A Bhurwal","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e013739","DOI":"10.1136\/bmjopen-2016-013739","article-title":"Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis","volume":"7","author":"O J Kennedy","year":"2017","journal-title":"BMJ Open"},{"key":"ref56","first-page":"Cd005004","article-title":"Green tea (Camellia sinensis) for the prevention of cancer","volume":"3","author":"T Filippini","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","article-title":"Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"11","author":"S Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/liv.13872","article-title":"Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes","volume":"38","author":"C H Tseng","year":"2018","journal-title":"Liver Int"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review","volume":"19","author":"V Cunha","year":"2020","journal-title":"Ann Hepatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1177\/1060028013503108","article-title":"Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C","volume":"47","author":"K Harris","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"S E Inzucchi","year":"2014","journal-title":"Jama"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"X Zhang","year":"2014","journal-title":"Hepatology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2016.04.031","article-title":"Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study","volume":"65","author":"H Vandenbulcke","year":"2016","journal-title":"J Hepatol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"M S Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjsurg.2019.05.016","article-title":"Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3\u202fcm \u2013 A retrospective cohort study","volume":"219","author":"Z Y Wang","year":"2020","journal-title":"Am J Surg"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/cid\/ciz860","article-title":"Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy","volume":"71","author":"J W Jang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/liv.12805","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Y Yang","year":"2015","journal-title":"Liver Int"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"G Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/hep.30988?download=true","article-title":"Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West","volume":"71","author":"H Dang","year":"2020","journal-title":"Hepatology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"B H Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","article-title":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis?","volume":"102","author":"F Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","article-title":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis?","volume":"102","author":"F Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"R Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"07","key":"ref75","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41416-022-01851-1","article-title":"Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify","volume":"127","author":"P Johnson","year":"2022","journal-title":"Br J Cancer"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apt.12370","article-title":"Surveillance for hepatocellular cancer with ultrasonography vs computed tomography -- a randomised study","volume":"38","author":"C Pocha","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"J C Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis","volume":"154","author":"K Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/MEG.0000000000001226","article-title":"Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy","volume":"30","author":"B G Song","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"e1001624","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"A G Singal","year":"2014","journal-title":"PLoS Med"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-021-08138-3","article-title":"PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma","volume":"21","author":"H Feng","year":"2021","journal-title":"BMC Cancer"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/CBM-190118","article-title":"Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma","volume":"29","author":"G Ricco","year":"2020","journal-title":"Cancer Biomark"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-018-9222-0","article-title":"Validation of a novel model for the early detection of hepatocellular carcinoma","volume":"16","author":"P Hemken","year":"2019","journal-title":"Clin Proteomics"},{"key":"ref84","first-page":"8868370","article-title":"The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients","volume":"2021","author":"F Xu","year":"2021","journal-title":"Dis Markers"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2014.11.005","article-title":"Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion","volume":"62","author":"N Pot\u00e9","year":"2015","journal-title":"J Hepatol"},{"issue":"08","key":"ref86","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/liv.14475","article-title":"The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy","volume":"40","author":"A Loglio","year":"2020","journal-title":"Liver Int"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis","volume":"18","author":"J Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score","volume":"28","author":"J Yang","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"08","key":"ref89","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/ph14080735","article-title":"GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients","volume":"14","author":"C Schotten","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/liv.15082","article-title":"Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study","volume":"42","author":"C Huang","year":"2022","journal-title":"Liver Int"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","article-title":"The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States","volume":"21","author":"N Tayob","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.32185","article-title":"GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis","volume":"75","author":"A Singal","year":"2022","journal-title":"Hepatology"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jgh3.12720","article-title":"Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis","volume":"6","author":"H Chan","year":"2022","journal-title":"JGH Open"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","article-title":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","volume":"20","author":"N Chalasani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review","volume":"158","author":"R Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41395-018-0207-4","article-title":"Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis","volume":"113","author":"J L Petrick","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"R Loomba","year":"2020","journal-title":"Gut"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"R K Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"R S Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742?download=true","article-title":"Liver biopsy","volume":"49","author":"D C Rockey","year":"2009","journal-title":"Hepatology"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gut.2008.149062","article-title":"Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis","volume":"57","author":"M A Silva","year":"2008","journal-title":"Gut"},{"issue":"S 02","key":"ref103","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/lt.22374?download=true","article-title":"Is tumor biopsy necessary?","volume":"17","author":"B M\u00fcllhaupt","year":"2011","journal-title":"Liver Transpl"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2014.04.046","article-title":"Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC","volume":"61","author":"D Fuks","year":"2014","journal-title":"J Hepatol"},{"key":"ref105","first-page":"215","volume-title":"Tumors of the liver and intrahepatic bile ducts","author":"V FM Paradis","year":"2019"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.1840220341","article-title":"Terminology of nodular hepatocellular lesions","volume":"22","year":"1995","journal-title":"Hepatology"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/hep.22709?download=true","article-title":"Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/his.13520?download=true","article-title":"Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"73","author":"A D Burt","year":"2018","journal-title":"Histopathology"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/1097-0142%28195405%297%3A3%3C462%3A%3AAID-CNCR2820070308%3E3.0.CO%3B2-E","article-title":"Primary carcinoma of the liver A study of 100 cases among 48,900 necropsies","volume":"7","author":"H A Edmondson","year":"1954","journal-title":"Cancer"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/1097-0142%2819950815%2976%3A4%3C579%3A%3AAID-CNCR2820760407%3E3.0.CO%3B2-D?download=true","article-title":"Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma","volume":"76","author":"U C Nzeako","year":"1995","journal-title":"Cancer"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/hep.21531?download=true","article-title":"Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis","volume":"45","author":"L Di Tommaso","year":"2007","journal-title":"Hepatology"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2008.11.014","article-title":"The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma","volume":"50","author":"L Di Tommaso","year":"2009","journal-title":"J Hepatol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis","volume":"275","author":"Y J Lee","year":"2015","journal-title":"Radiology"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2463\/mrms.2014-0149","article-title":"Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma","volume":"15","author":"N Chen","year":"2016","journal-title":"Magn Reson Med Sci"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/apt.12166","article-title":"Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study","volume":"37","author":"A Granito","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jmri.22588","article-title":"Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging","volume":"34","author":"H Haradome","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00535-012-0571-6","article-title":"Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT","volume":"47","author":"T Inoue","year":"2012","journal-title":"J Gastroenterol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"e111935","DOI":"10.1371\/journal.pone.0111935","article-title":"Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?","volume":"9","author":"B Maiwald","year":"2014","journal-title":"PLoS One"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/liv.12550","article-title":"Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT","volume":"34","author":"V Y Park","year":"2014","journal-title":"Liver Int"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/RLI.0b013e3181c5faf7","article-title":"or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging","volume":"45","year":"2010","journal-title":"Invest Radiol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00535-015-1097-5","article-title":"Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study","volume":"51","author":"M Tsurusaki","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.1840380430","article-title":"MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation","volume":"38","author":"M Burrel","year":"2003","journal-title":"Hepatology"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00330-012-2691-z","article-title":"Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging","volume":"23","author":"M Di Martino","year":"2013","journal-title":"Eur Radiol"},{"issue":"02","key":"ref124","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/a-1220-8561","article-title":"Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS\/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma \u2013 A Prospective Multicenter DEGUM Study","volume":"42","author":"B Schellhaas","year":"2021","journal-title":"Ultraschall Med"},{"issue":"10","key":"ref125","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1007\/s00330-021-07872-3","article-title":"Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS\u00ae\/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study","volume":"31","author":"D Strobel","year":"2021","journal-title":"Eur Radiol"},{"issue":"11","key":"ref126","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.ultrasmedbio.2021.07.010","article-title":"Contrast-Enhanced Ultrasound Patterns for the Non-invasive Diagnosis of Hepatocellular Carcinoma: A Prospective Multicenter Study in Histologically Proven Liver Lesions in a Real-Life Setting Demonstrating the Benefit of Extended Late Phase Observation","volume":"47","author":"B Schellhaas","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-015-3241-0","article-title":"Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET\/CT in hepatocellular carcinoma","volume":"43","author":"M A Castilla-Lievre","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref128","first-page":"3569","article-title":"Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET\/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT","volume":"17","author":"C Chotipanich","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jhep.2015.11.033","article-title":"Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation","volume":"64","author":"G Hong","year":"2016","journal-title":"J Hepatol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1097\/RLU.0000000000001545","article-title":"Predictive Value of 18F-FDG PET\/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation","volume":"42","author":"C Y Lin","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2010.07.025","article-title":"Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization","volume":"54","author":"K Khalili","year":"2011","journal-title":"J Hepatol"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15403\/jgld.2014.1121.252.chu","article-title":"Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance","volume":"25","author":"A Giorgio","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/MEG.0000000000000916","article-title":"Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS","volume":"29","author":"B Schellhaas","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.27304","article-title":"LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions","volume":"61","author":"D G Mitchell","year":"2015","journal-title":"Hepatology"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"J M Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1477-2574.2012.00617.x","article-title":"Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system","volume":"15","author":"A C Chan","year":"2013","journal-title":"HPB (Oxford)"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire","volume":"31","author":"S Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"P J Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"S 01","key":"ref139","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000173428","article-title":"Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score","volume":"75","author":"S Kitai","year":"2008","journal-title":"Oncology"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/cncr.10384","article-title":"Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients","volume":"94","author":"T W Leung","year":"2002","journal-title":"Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"J A Marrero","year":"2005","journal-title":"Hepatology"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"D J Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.transproceed.2009.03.054","article-title":"Validation of the BCLC prognostic system in surgical hepatocellular cancer patients","volume":"41","author":"A Vitale","year":"2009","journal-title":"Transplant Proc"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"T Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cgh.2016.10.036","article-title":"Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy","volume":"15","author":"J H Sohn","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"97428","DOI":"10.18632\/oncotarget.22134","article-title":"Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database","volume":"8","author":"A Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11605-018-3690-4","article-title":"Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals","volume":"22","author":"F Krenzien","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/SLA.0b013e3181bd582b","article-title":"Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation","volume":"250","author":"D Cherqui","year":"2009","journal-title":"Ann Surg"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/bjs.7393?download=true","article-title":"Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma","volume":"98","author":"S Eguchi","year":"2011","journal-title":"Br J Surg"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study","volume":"64","author":"G Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/lt.24963","article-title":"Pro (With Caution): Extended oncologic indications in liver transplantation","volume":"24","author":"V Mazzaferro","year":"2018","journal-title":"Liver Transpl"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"V Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/SLA.0000000000002381","article-title":"Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium","volume":"266","author":"V G Agopian","year":"2017","journal-title":"Ann Surg"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.rili_baek_OrgaWlOvLeberTx2019092","article-title":"Bundes\u00e4rztekammer. Richtlinien zur Organtransplantation gem \u00a7 16 TPG","year":"2019","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lt.25731","article-title":"Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma","volume":"26","author":"J von Felden","year":"2020","journal-title":"Liver Transpl"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"F Y Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"V Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.30570","article-title":"Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol","volume":"70","author":"J Sinha","year":"2019","journal-title":"Hepatology"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/cancers12020452","article-title":"Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort","volume":"12","author":"Q Lai","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","article-title":"Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study","volume":"16","author":"N Mehta","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/lt.20837?download=true","article-title":"Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma","volume":"12","author":"G Otto","year":"2006","journal-title":"Liver Transpl"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jamcollsurg.2018.03.025","article-title":"Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients","volume":"226","author":"S Di Sandro","year":"2018","journal-title":"J Am Coll Surg"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/hep.28339?download=true","article-title":"Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection","volume":"63","author":"J Ferrer-F\u00e0brega","year":"2016","journal-title":"Hepatology"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jso.23916?download=true","article-title":"Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation","volume":"111","author":"O Scatton","year":"2015","journal-title":"J Surg Oncol"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.29468?download=true","article-title":"Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis","volume":"67","author":"R J de Haas","year":"2018","journal-title":"Hepatology"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/SLA.0000000000001442","article-title":"Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?","volume":"264","author":"P Bhangui","year":"2016","journal-title":"Ann Surg"},{"key":"ref167","first-page":"478","article-title":"Is there a place for liver grafting for malignancy?","volume":"20","author":"R Pichlmayr","year":"1988","journal-title":"Transplant Proc"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/lt.20128?download=true","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis","volume":"10","author":"S Roayaie","year":"2004","journal-title":"Liver Transpl"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/lt.20140?download=true","article-title":"Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome","volume":"10","author":"K Shetty","year":"2004","journal-title":"Liver Transpl"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/lt.25056","article-title":"Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma","volume":"24","author":"H W Lee","year":"2018","journal-title":"Liver Transpl"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/lt.23652","article-title":"Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma","volume":"19","author":"K Berry","year":"2013","journal-title":"Liver Transpl"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-6143.2009.02750.x","article-title":"Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor","volume":"10","author":"E Vibert","year":"2010","journal-title":"Am J Transplant"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"F Y Yao","year":"2015","journal-title":"Hepatology"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/lt.23904?download=true","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"B Hameed","year":"2014","journal-title":"Liver Transpl"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"J K Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/hep.30413?download=true","article-title":"500 ng\/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/hep.26972?download=true","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"59","author":"P Martin","year":"2014","journal-title":"Hepatology"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.transproceed.2009.03.080","article-title":"Elderly versus young liver transplant recipients: patient and graft survival","volume":"41","author":"G L Adani","year":"2009","journal-title":"Transplant Proc"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/lt.21181?download=true","article-title":"Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival","volume":"13","author":"T J Cross","year":"2007","journal-title":"Liver Transpl"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2478\/pjs-2013-0087","article-title":"Short and long-term outcomes after primary liver transplantation in elderly patients","volume":"85","author":"M Gr\u0105t","year":"2013","journal-title":"Pol Przegl Chir"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0025-6196(11)60667-8","article-title":"Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years","volume":"84","author":"J F Aduen","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archsurg.142.8.775","article-title":"Outcome of liver transplantation in septuagenarians: a single-center experience","volume":"142","author":"G S Lipshutz","year":"2007","journal-title":"Arch Surg"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/TP.0000000000000524","article-title":"Living Donor Liver Transplantation in Patients 70 Years or Older","volume":"99","author":"A Oezcelik","year":"2015","journal-title":"Transplantation"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12072-011-9286-7","article-title":"Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years","volume":"6","author":"C B Taner","year":"2012","journal-title":"Hepatol Int"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/00365521.2016.1236396","article-title":"Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"52","author":"X Huang","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis","volume":"67","author":"L Kulik","year":"2018","journal-title":"Hepatology"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0000000000001936","article-title":"Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation","volume":"102","author":"D Sneiders","year":"2018","journal-title":"Transplantation"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"P A Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref190","first-page":"143","article-title":"Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival","volume":"6","author":"E W Beal","year":"2016","journal-title":"Front Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transproceed.2017.09.063","article-title":"Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?","volume":"50","author":"P Cascales-Campos","year":"2018","journal-title":"Transplant Proc"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/liv.12966","article-title":"Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy","volume":"36","author":"A Finkenstedt","year":"2016","journal-title":"Liver Int"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10353-017-0487-8","article-title":"Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation","volume":"49","author":"G P Gy\u00f6ri","year":"2017","journal-title":"Eur Surg"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1038\/srep41624","article-title":"Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma","volume":"7","author":"L Jianyong","year":"2017","journal-title":"Sci Rep"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.3748\/wjg.v23.i20.3690","article-title":"Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation","volume":"23","author":"D Nicolini","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","article-title":"Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization","volume":"93","author":"A Gabr","year":"2017","journal-title":"Eur J Radiol"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/lt.25492?download=true","article-title":"The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation","volume":"25","author":"Q Lai","year":"2019","journal-title":"Liver Transpl"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1148\/radiol.2016160288","article-title":"Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation","volume":"282","author":"H C Oligane","year":"2017","journal-title":"Radiology"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/lt.21033?download=true","article-title":"Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma","volume":"13","author":"G Millonig","year":"2007","journal-title":"Liver Transpl"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/lt.22397?download=true","article-title":"Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy","volume":"17","author":"A Cucchetti","year":"2011","journal-title":"Liver Transpl"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/lt.23706?download=true","article-title":"Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation","volume":"19","author":"Q Lai","year":"2013","journal-title":"Liver Transpl"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/ajt.12684?download=true","article-title":"Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size","volume":"14","author":"D J Kim","year":"2014","journal-title":"Am J Transplant"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2010.262","article-title":"Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma","volume":"303","author":"A Riaz","year":"2010","journal-title":"Jama"},{"issue":"05","key":"ref204","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/hep.31992","article-title":"Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant","volume":"74","author":"T Wong","year":"2021","journal-title":"Hepatology"},{"issue":"01","key":"ref205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis","volume":"67","author":"G Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"ref206","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2019.10.006","article-title":"Extended criteria for liver transplantation in hepatocellular carcinoma A retrospective, multicentric validation study in Belgium","author":"H Degroote","year":"2019","journal-title":"Surg Oncol"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: A systematic review and pooled analysis","volume":"21","author":"N D Parikh","year":"2015","journal-title":"Liver Transpl"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jamcollsurg.2016.12.020","article-title":"Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions","volume":"224","author":"W C Chapman","year":"2017","journal-title":"J Am Coll Surg"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00508-016-1046-1","article-title":"Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (\u00d6GGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)","volume":"128","author":"I Graziadei","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 20 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma","volume":"154","author":"V Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000002964","article-title":"Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies","volume":"268","author":"K J Halazun","year":"2018","journal-title":"Ann Surg"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.21037\/hbsn.2016.08.07","article-title":"Living donor liver transplantation for hepatocellular carcinoma in Seoul National University","volume":"5","author":"S K Hong","year":"2016","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref213","first-page":"224","article-title":"(18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma","volume":"5","author":"A Kornberg","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/tri.13586","article-title":"Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion \u2013 a multi-center retrospective cohort study","volume":"33","author":"M Assalino","year":"2020","journal-title":"Transpl Int"},{"key":"ref215","first-page":"182","article-title":"Controversies in criteria for liver transplantation in hepatocellular carcinoma","volume":"32","author":"N D Parikh","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma","volume":"151","author":"R Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00268-016-3682-z","article-title":"Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation","volume":"41","author":"G M Ettorre","year":"2017","journal-title":"World J Surg"},{"key":"ref218","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a downstaging therapy for liver transplantation","author":"B Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"ref219","first-page":"227","article-title":"Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review","volume":"16","author":"N Golse","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients \u2013 a prospective, randomized, double-blind, phase III trial","volume":"15","author":"K Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/TP.0000000000003196","article-title":"Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma Working Group Report From the ILTS Transplant Oncology Consensus Conference","volume":"104","author":"M Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajt.15697?download=true","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"E C Verna","year":"2020","journal-title":"Am J Transplant"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/lt.20391?download=true","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression","volume":"11","author":"M Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"key":"ref224","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"M Vivarelli","year":"2008","journal-title":"Ann Surg"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"M Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"ref226","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3748\/wjg.v12.i45.7319","article-title":"Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients","volume":"12","author":"T Decaens","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref227","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0000000000002532","article-title":"Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation","volume":"103","author":"P S Tan","year":"2019","journal-title":"Transplantation"},{"key":"ref228","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"C Duvoux","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fphar.2016.00387","article-title":"Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature","volume":"7","author":"G Tarantino","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/lt.23658?download=true","article-title":"Calcineurin inhibitor-free mycophenolate mofetil\/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial","volume":"19","author":"L Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/lt.21827?download=true","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"P De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study","volume":"99","author":"L Fischer","year":"2015","journal-title":"Transplantation"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"E K Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"F Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref235","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"V Paradis","year":"2009","journal-title":"Hepatology"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"F Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/ijc.25797?download=true","article-title":"Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis","volume":"128","author":"J Ertle","year":"2011","journal-title":"Int J Cancer"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.suronc.2014.11.001","article-title":"Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review","volume":"23","author":"Y Zhou","year":"2014","journal-title":"Surg Oncol"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.surg.2012.09.015","article-title":"Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver","volume":"153","author":"W Faber","year":"2013","journal-title":"Surgery"},{"key":"ref240","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/bjs.8963?download=true","article-title":"Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome","volume":"100","author":"F Cauchy","year":"2013","journal-title":"Br J Surg"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hpb.2019.07.007","article-title":"Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver","volume":"22","author":"B V Dasari","year":"2020","journal-title":"HPB (Oxford)"},{"key":"ref242","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101441","article-title":"The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?","volume":"11","author":"M Ju","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejso.2018.04.018","article-title":"Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis","volume":"44","author":"D Moris","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1245\/s10434-013-3211-3","article-title":"Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis","volume":"21","author":"D J Arnaoutakis","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2007.03.002","article-title":"Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers","volume":"205","author":"H Lang","year":"2007","journal-title":"J Am Coll Surg"},{"key":"ref246","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11605-006-0023-9","article-title":"Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver A 116-case European series","volume":"11","author":"T B\u00e8ge","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"ref247","first-page":"4195076","article-title":"Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center","volume":"2018","author":"E M Teegen","year":"2018","journal-title":"Int J Surg Oncol"},{"key":"ref248","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jso.25184?download=true","article-title":"Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma","volume":"118","author":"Y Y Wang","year":"2018","journal-title":"J Surg Oncol"},{"key":"ref249","doi-asserted-by":"publisher","first-page":"016005","DOI":"10.1088\/1752-7163\/aa820b","article-title":"Kinetic validation of the LiMAx test during 10 000 intravenous (13)C-methacetin breath tests","volume":"12","author":"T M Rubin","year":"2017","journal-title":"J Breath Res"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","article-title":"Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity","volume":"250","author":"M Stockmann","year":"2009","journal-title":"Ann Surg"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"e0190512","DOI":"10.1371\/journal.pone.0190512","article-title":"Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis","volume":"13","author":"Z Huang","year":"2018","journal-title":"PLoS One"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.mayocp.2018.12.020","article-title":"Portal Hypertension and Related Complications: Diagnosis and Management","volume":"94","author":"D A Simonetto","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref253","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hep.27745","article-title":"The role of hepatic resection in the treatment of hepatocellular cancer","volume":"62","author":"S Roayaie","year":"2015","journal-title":"Hepatology"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"T Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/SLA.0b013e31828329b8","article-title":"A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL\/AASLD recommendations?: an observational study of the HCC East-West study group","volume":"257","author":"G Torzilli","year":"2013","journal-title":"Ann Surg"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v10.i6.433","article-title":"Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence","volume":"10","author":"Y X Koh","year":"2018","journal-title":"World J Hepatol"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000001866","article-title":"Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria","volume":"264","author":"V M Zaydfudim","year":"2016","journal-title":"Ann Surg"},{"key":"ref258","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1245\/s10434-020-08452-3","article-title":"Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria","volume":"27","author":"D I Tsilimigras","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"ref259","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4254\/wjh.v7.i2.245","article-title":"Surgical management of hepatocellular carcinoma","volume":"7","author":"T C Pang","year":"2015","journal-title":"World J Hepatol"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.hpb.2017.04.010","article-title":"A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence","volume":"19","author":"X Feng","year":"2017","journal-title":"HPB (Oxford)"},{"key":"ref261","first-page":"619","article-title":"Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka","volume":"261","author":"G Wakabayashi","year":"2015","journal-title":"Ann Surg"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/SLA.0000000000002151","article-title":"Laparoscopic Liver Resection: An Ongoing Revolution","volume":"265","author":"D Cherqui","year":"2017","journal-title":"Ann Surg"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.suronc.2018.10.005","article-title":"Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis","volume":"27","author":"A Andreou","year":"2018","journal-title":"Surg Oncol"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.suronc.2018.12.001","article-title":"Laparoscopic liver surgery in cirrhosis \u2013 Addressing lesions in posterosuperior segments","volume":"28","author":"P K Haber","year":"2019","journal-title":"Surg Oncol"},{"key":"ref265","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00464-018-6426-3","article-title":"Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry","volume":"33","author":"G B Levi Sandri","year":"2019","journal-title":"Surg Endosc"},{"key":"ref266","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13304-015-0323-2","article-title":"Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience","volume":"67","author":"E Felli","year":"2015","journal-title":"Updates Surg"},{"key":"ref267","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"M S Chen","year":"2006","journal-title":"Ann Surg"},{"key":"ref268","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"K Feng","year":"2012","journal-title":"J Hepatol"},{"key":"ref269","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"J Huang","year":"2010","journal-title":"Ann Surg"},{"key":"ref270","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/bjs.10677","article-title":"Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma","volume":"104","author":"K KC Ng","year":"2017","journal-title":"Br J Surg"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT","volume":"61","author":"L Yin","year":"2014","journal-title":"J Hepatol"},{"key":"ref272","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"ref273","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5152\/eajm.2014.07","article-title":"Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study","volume":"46","author":"M A Wahab","year":"2014","journal-title":"Eurasian J Med"},{"key":"ref274","first-page":"898","article-title":"Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients","volume":"53","author":"G Ramacciato","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"ref275","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jgh.12791","article-title":"Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial","volume":"30","author":"G G Di Costanzo","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"ref276","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.dld.2013.10.015","article-title":"An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"46","author":"A Cucchetti","year":"2014","journal-title":"Dig Liver Dis"},{"key":"ref277","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-230X-11-143","article-title":"Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma","volume":"11","author":"H Nishikawa","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"ref278","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00330-018-5902-4","article-title":"Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database","volume":"29","author":"J Uhlig","year":"2019","journal-title":"Eur Radiol"},{"key":"ref279","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jus.2009.05.003","article-title":"Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis","volume":"12","author":"A Salmi","year":"2009","journal-title":"J Ultrasound"},{"key":"ref280","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jso.24113","article-title":"Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma","volume":"113","author":"S Mohanty","year":"2016","journal-title":"J Surg Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2169\/internalmedicine.0973-18","article-title":"Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis","volume":"58","author":"R Yamauchi","year":"2019","journal-title":"Intern Med"},{"key":"ref282","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiology.210.3.r99fe40655","article-title":"Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection","volume":"210","author":"T Livraghi","year":"1999","journal-title":"Radiology"},{"key":"ref283","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1148\/radiol.2281020718","article-title":"Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection","volume":"228","author":"R A Lencioni","year":"2003","journal-title":"Radiology"},{"key":"ref284","first-page":"1714","article-title":"or =4 cm","volume":"127","year":"2004","journal-title":"Gastroenterology"},{"key":"ref285","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference European Association for the Study of the Liver","volume":"35","author":"J Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"ref286","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"S Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"ref287","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/00365520701885481?needAccess=true","article-title":"Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial","volume":"43","author":"F Brunello","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"ref288","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","article-title":"Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less","volume":"54","author":"S M Lin","year":"2005","journal-title":"Gut"},{"issue":"S 01","key":"ref289","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000048278","article-title":"Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation","volume":"62","author":"S Shiina","year":"2002","journal-title":"Oncology"},{"key":"ref290","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/hep.30591?download=true","article-title":"Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis","volume":"69","author":"K Hara","year":"2019","journal-title":"Hepatology"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Z W Peng","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref292","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/bjs.10061","article-title":"Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria","volume":"103","author":"H Liu","year":"2016","journal-title":"Br J Surg"},{"key":"ref293","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1080\/00365521.2018.1548645","article-title":"Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma","volume":"53","author":"K Endo","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"ref294","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.hpb.2017.08.011","article-title":"Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping","volume":"19","author":"S Fukutomi","year":"2017","journal-title":"HPB (Oxford)"},{"key":"ref295","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00261-018-1464-9","article-title":"Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone","volume":"43","author":"A R Smolock","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"ref296","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00270-012-0341-0","article-title":"Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session","volume":"35","author":"G Bonomo","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref297","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"C M Lo","year":"2002","journal-title":"Hepatology"},{"key":"ref298","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"J Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref299","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"R Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"ref300","doi-asserted-by":"crossref","first-page":"348","DOI":"10.21037\/jgo.2019.01.01","article-title":"Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC)","volume":"10","author":"R Yamada","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"J M Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref302","first-page":"Cd011313","article-title":"Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma","volume":"1","author":"O Abdel-Rahman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref303","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/s-0043-124870","article-title":"Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial","volume":"50","author":"J Yang","year":"2018","journal-title":"Endoscopy"},{"key":"ref304","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00330-016-4548-3","article-title":"Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma","volume":"27","author":"J M Ludwig","year":"2017","journal-title":"Eur Radiol"},{"key":"ref305","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.2147\/OTT.S175715","article-title":"Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"11","author":"A Casadei Gardini","year":"2018","journal-title":"Onco Targets Ther"},{"key":"ref306","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.12750?download=true","article-title":"Pilot randomized trial of selective internal radiation therapy vs chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"F T Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"ref307","doi-asserted-by":"crossref","first-page":"e0184597","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials","volume":"12","author":"K Katsanos","year":"2017","journal-title":"PLoS One"},{"key":"ref308","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"M B Pitton","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref309","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis","volume":"39","author":"L Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref310","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"R Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00259-018-3968-5","article-title":"Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies","volume":"45","author":"B Sangro","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref312","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jvir.2016.03.046","article-title":"Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma","volume":"27","author":"G E Johnson","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"ref313","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944?download=true","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"P Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"ref314","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451?download=true","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"B Sangro","year":"2011","journal-title":"Hepatology"},{"key":"ref315","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/hep.21980?download=true","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"L M Kulik","year":"2008","journal-title":"Hepatology"},{"key":"ref316","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014?download=true","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"V Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"ref317","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"R Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"ref318","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review","volume":"129","author":"C H Rim","year":"2018","journal-title":"Radiother Oncol"},{"issue":"08","key":"ref319","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","article-title":"Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group","volume":"46","author":"R Salem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"05","key":"ref320","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"H Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"01","key":"ref321","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"E Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"05","key":"ref322","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"R Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref323","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"V Vilgrain","year":"2017","journal-title":"The Lancet Oncology"},{"key":"ref324","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"P KH Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"ref326","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"A Vogel","year":"2018","journal-title":"Ann Oncol"},{"issue":"07","key":"ref327","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/hepr.13647","article-title":"Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies","volume":"51","author":"T Eriguchi","year":"2021","journal-title":"Hepatol Res"},{"issue":"01","key":"ref328","doi-asserted-by":"crossref","first-page":"100594","DOI":"10.1016\/j.jhepr.2022.100594","article-title":"Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis","volume":"5","author":"C Rim","year":"2023","journal-title":"JHEP Rep"},{"key":"ref329","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2022.11.013","article-title":"Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial","author":"T Craig","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"ref330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","article-title":"Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"131","author":"C Rim","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma","volume":"100","author":"E Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref332","doi-asserted-by":"crossref","first-page":"653141","DOI":"10.3389\/fonc.2021.653141","article-title":"Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)","volume":"11","author":"T Brunner","year":"2021","journal-title":"Front Oncol"},{"issue":"05","key":"ref333","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","article-title":"Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"196","author":"M Guckenberger","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"ref334","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijrobp.2007.09.056","article-title":"Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis","volume":"71","author":"M Mizumoto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref335","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ijrobp.2008.10.073","article-title":"A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma","volume":"74","author":"N Fukumitsu","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref336","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijrobp.2009.02.030","article-title":"Proton beam therapy for large hepatocellular carcinoma","volume":"76","author":"S Sugahara","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"01","key":"ref337","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4143\/crt.2013.218","article-title":"Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma","volume":"47","author":"T Kim","year":"2015","journal-title":"Cancer Res Treat"},{"key":"ref338","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ijrobp.2010.03.015","article-title":"Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract","volume":"80","author":"H Nakayama","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref339","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","article-title":"Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis","volume":"95","author":"D A Bush","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref340","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"34","author":"T S Hong","year":"2016","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref341","doi-asserted-by":"crossref","first-page":"570","DOI":"10.14338\/IJPT-15-00035.2","article-title":"Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience","volume":"2","author":"M Mizumoto","year":"2016","journal-title":"Int J Part Ther"},{"key":"ref342","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.07.1700","article-title":"Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival","volume":"78","author":"K Mohnike","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref343","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00270-018-2127-5","article-title":"Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial","volume":"42","author":"K Mohnike","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref344","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00066-014-0781-3","article-title":"CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma","volume":"191","author":"F Collettini","year":"2015","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"ref345","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)","volume":"29","author":"T Comito","year":"2022","journal-title":"Curr Oncol"},{"issue":"02","key":"ref346","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijrobp.2022.05.021","article-title":"Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial","volume":"114","author":"M Buckstein","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"05","key":"ref347","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial","volume":"4","author":"S Yoon","year":"2018","journal-title":"JAMA Oncol"},{"issue":"06","key":"ref348","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"1","author":"Y Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref349","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00261-017-1334-x","article-title":"LI-RADS categories: concepts, definitions, and criteria","volume":"43","author":"C Santillan","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"ref350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00261-017-1291-4","article-title":"LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents","volume":"43","author":"C Santillan","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"S 01","key":"ref351","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000111714","article-title":"Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy","volume":"72","author":"S Takahashi","year":"2007","journal-title":"Oncology"},{"key":"ref352","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1572-0241.2007.01604.x","article-title":"Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response","volume":"103","author":"A Guglielmi","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref353","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jvir.2009.11.014","article-title":"Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas","volume":"21","author":"J H Yoon","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"ref354","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1477-2574.2010.00181.x","article-title":"Pretreatment assessment of hepatocellular carcinoma: expert consensus statement","volume":"12","author":"J N Vauthey","year":"2010","journal-title":"HPB (Oxford)"},{"key":"ref355","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1102\/1470-7330.2007.9047","article-title":"Post-treatment imaging of liver tumours","volume":"7 Spec No A","author":"W Schima","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref356","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/s-0029-1245934","article-title":"Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies","volume":"32","author":"M Frieser","year":"2011","journal-title":"Ultraschall Med"},{"key":"ref357","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000218342","article-title":"Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma","volume":"27","author":"D Schacherer","year":"2009","journal-title":"Dig Dis"},{"key":"ref358","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2008.02.005","article-title":"Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma","volume":"48","author":"R Lencioni","year":"2008","journal-title":"J Hepatol"},{"key":"ref359","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00270-009-9736-y","article-title":"Quality improvement guidelines for radiofrequency ablation of liver tumours","volume":"33","author":"L Crocetti","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref360","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1440-1746.2009.06115.x?download=true","article-title":"Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation","volume":"25","author":"M C Tsai","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","article-title":"New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma","volume":"19","author":"R Lencioni","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref362","doi-asserted-by":"crossref","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis","volume":"10","author":"B Vincenzi","year":"2015","journal-title":"PLoS One"},{"key":"ref363","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745?articleTools=true","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref364","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref365","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"The Lancet"},{"key":"ref366","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"The Lancet"},{"key":"ref367","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002?articleTools=true","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"G K Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"ref368","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"A X Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"04","key":"ref369","first-page":"2379","article-title":"Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"A Facciorusso","year":"2021","journal-title":"Am J Transl Res"},{"key":"ref370","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"K Abou-Alfa Ghassan","year":"2022","journal-title":"NEJM Evidence"},{"key":"ref371","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857?articleTools=true","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref372","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"A X Zhu","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"04","key":"ref373","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"A Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"07","key":"ref374","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"P Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref375","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"C Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref376","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"P J Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref377","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"A X Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref378","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"A L Cheng","year":"2013","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref379","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"T Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref380","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study","volume":"65","author":"J A Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-16-0919","article-title":"Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study","volume":"23","author":"T M Ganten","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref382","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10637-018-0621-x","article-title":"Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study","volume":"36","author":"C RG Leal","year":"2018","journal-title":"Invest New Drugs"},{"key":"ref383","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","article-title":"Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","volume":"24","author":"T Pressiani","year":"2013","journal-title":"Ann Oncol"},{"key":"ref384","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","article-title":"Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors","volume":"33","author":"S Ogasawara","year":"2015","journal-title":"Invest New Drugs"},{"issue":"01","key":"ref385","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12885-022-09453-z","article-title":"Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial","volume":"22","author":"A El-Khoueiry","year":"2022","journal-title":"BMC Cancer"},{"key":"ref386","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221116608","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function","volume":"14","author":"J Huynh","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"ref387","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/cncr.32206?download=true","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series","volume":"125","author":"S Kambhampati","year":"2019","journal-title":"Cancer"},{"issue":"03","key":"ref388","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"M Kudo","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"ref389","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort","volume":"49","author":"B Scheiner","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"ref390","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/cancers12123830","article-title":"Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma","volume":"12","author":"S Spahn","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"04","key":"ref391","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study","volume":"76","author":"A D\u2019Alessio","year":"2022","journal-title":"Hepatology"},{"key":"ref392","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221080298","article-title":"Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience","volume":"14","author":"T de Castro","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"ref393","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"V Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref394","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"R Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"ref395","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"T Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"04","key":"ref396","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma","volume":"11","author":"M Kudo","year":"2022","journal-title":"Liver Cancer"},{"issue":"20","key":"ref397","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study","volume":"127","author":"X Ding","year":"2021","journal-title":"Cancer"},{"key":"ref398","doi-asserted-by":"crossref","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study","volume":"13","author":"M Cai","year":"2022","journal-title":"Front Immunol"},{"issue":"06","key":"ref399","doi-asserted-by":"crossref","first-page":"e004205","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"B Marinelli","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"01","key":"ref400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cam4.4937","article-title":"Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis","volume":"12","author":"W Fan","year":"2023","journal-title":"Cancer Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"J Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"ref402","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"M Kudo","year":"2020","journal-title":"Gut"},{"key":"ref403","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/hepr.13394","article-title":"Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)","volume":"49","author":"M Kudo","year":"2019","journal-title":"Hepatol Res"},{"key":"ref404","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JCO.2021.39.3_suppl.270","article-title":"TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)","volume":"39","author":"M Kudo","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"ref405","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"03","key":"ref406","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"R Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref407","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12072-020-10064-8","article-title":"Clinical benefits of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"14","author":"Q Rao","year":"2020","journal-title":"Hepatol Int"},{"issue":"05","key":"ref408","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/cer-2020-0236","article-title":"Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma","volume":"10","author":"N Parikh","year":"2021","journal-title":"J Comp Eff Res"},{"key":"ref409","doi-asserted-by":"crossref","first-page":"626984","DOI":"10.3389\/fonc.2021.626984","article-title":"The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"11","author":"S He","year":"2021","journal-title":"Front Oncol"},{"key":"ref410","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"A B El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"A X Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref412","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","article-title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"167","author":"M Kudo","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref413","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"R S Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref414","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study","volume":"40","author":"S Qin","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"ref415","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"T Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref416","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41575-022-00580-3","article-title":"A framework for fibrolamellar carcinoma research and clinical trials","volume":"19","author":"T Dinh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref417","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1249484","article-title":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma","volume":"343","author":"J Honeyman","year":"2014","journal-title":"Science"},{"issue":"01","key":"ref418","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10620-020-06135-3","article-title":"Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study","volume":"66","author":"D Ramai","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"04","key":"ref419","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"L Rimassa","year":"2021","journal-title":"J Hepatol"},{"issue":"11","key":"ref420","doi-asserted-by":"crossref","first-page":"104313","DOI":"10.1016\/j.ejmg.2021.104313","article-title":"Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas","volume":"64","author":"H Wege","year":"2021","journal-title":"Eur J Med Genet"},{"issue":"03","key":"ref421","doi-asserted-by":"crossref","first-page":"554","DOI":"10.21037\/jgo.2019.01.35","article-title":"Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma","volume":"10","author":"S Chakrabarti","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"01","key":"ref422","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000338242","article-title":"Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma","volume":"5","author":"P Gras","year":"2012","journal-title":"Case Rep Oncol"},{"issue":"03","key":"ref423","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2003.10.103","article-title":"Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma","volume":"21","author":"Y Patt","year":"2003","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref424","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/2326-6066.CIR-18-0499","article-title":"Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma","volume":"7","author":"A Kim","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"ref425","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.3390\/cancers14215347","article-title":"Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors","volume":"14","author":"K Chen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref426","doi-asserted-by":"crossref","first-page":"e005620","DOI":"10.1136\/jitc-2022-005620","article-title":"Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab","volume":"10","author":"R Berger","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"ref427","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2020-320604","article-title":"Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma","volume":"69","author":"E De Toni","year":"2020","journal-title":"Gut"},{"issue":"07","key":"ref428","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000524872","article-title":"Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report","volume":"45","author":"S Kang","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"02","key":"ref429","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"I Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"01","key":"ref430","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/cancers15010301","article-title":"The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives","volume":"15","author":"J Eschrich","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"01","key":"ref431","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.jhepr.2020.100174","article-title":"New insights into the pathophysiology and clinical care of rare primary liver cancers","volume":"3","author":"E Gigante","year":"2021","journal-title":"JHEP Rep"},{"issue":"06","key":"ref432","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes","volume":"35","author":"R Xue","year":"2019","journal-title":"Cancer Cell"},{"issue":"05","key":"ref433","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1159\/000525488","article-title":"Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma","volume":"11","author":"E Gigante","year":"2022","journal-title":"Liver Cancer"},{"issue":"06","key":"ref434","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.14813","article-title":"Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"41","author":"E Kim","year":"2021","journal-title":"Liver Int"},{"issue":"08","key":"ref435","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/cas.13656","article-title":"Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma","volume":"109","author":"S Kobayashi","year":"2018","journal-title":"Cancer Sci"},{"issue":"02","key":"ref436","doi-asserted-by":"crossref","first-page":"347","DOI":"10.21037\/jgo.2017.03.03","article-title":"Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy","volume":"8","author":"J Rogers","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"ref437","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2018.7053","article-title":"Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience","volume":"16","author":"N Trikalinos","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"03","key":"ref438","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2017.413","article-title":"Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study","volume":"118","author":"M Salimon","year":"2018","journal-title":"Br J Cancer"},{"key":"ref439","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"J Bruix","year":"2015","journal-title":"Lancet Oncol"},{"issue":"09","key":"ref440","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity","volume":"2","author":"W Ho","year":"2021","journal-title":"Nat Cancer"},{"issue":"03","key":"ref441","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"A Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref442","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"T Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"04","key":"ref443","doi-asserted-by":"crossref","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Y Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref444","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children\u2019s Cancer Group intergroup study","volume":"20","author":"H M Katzenstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref445","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2002.06.102","article-title":"Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group","volume":"20","author":"P Czauderna","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref446","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JHC.S94008","article-title":"Pediatric hepatocellular carcinoma: challenges and solutions","volume":"4","author":"I Schmid","year":"2017","journal-title":"J Hepatocell Carcinoma"},{"key":"ref447","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/pbc.23295","article-title":"Sorafenib and cisplatin\/doxorubicin (PLADO) in pediatric hepatocellular carcinoma","volume":"58","author":"I Schmid","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"ref448","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clnu.2014.11.007","article-title":"Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC)","volume":"34","author":"K Sch\u00fctte","year":"2015","journal-title":"Clin Nutr"},{"key":"ref449","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.hpb.2019.01.003","article-title":"Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma","volume":"21","author":"T H Huang","year":"2019","journal-title":"HPB (Oxford)"},{"key":"ref450","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"J Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"ref451","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13304-011-0121-4","article-title":"Nutritional aspects in patient undergoing liver resection","volume":"63","author":"R Ciuni","year":"2011","journal-title":"Updates Surg"},{"key":"ref452","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jcsm.12383","article-title":"GLIM criteria for the diagnosis of malnutrition \u2013 A consensus report from the global clinical nutrition community","volume":"10","author":"T Cederholm","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref453","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","article-title":"Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma","volume":"63","author":"N Fujiwara","year":"2015","journal-title":"J Hepatol"},{"key":"ref454","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.31557\/APJCP.2020.21.11.3285","article-title":"Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients","volume":"21","author":"H Badran","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref455","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02794-3","article-title":"Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab","author":"N Kim","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref456","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12876-019-1152-4","article-title":"\u201cSarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study\u201d","volume":"19","author":"Y Mardian","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref457","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/SLA.0000000000000743","article-title":"Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma","volume":"261","author":"T Voron","year":"2015","journal-title":"Ann Surg"},{"key":"ref458","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"M Plauth","year":"2019","journal-title":"Clin Nutr"},{"key":"ref459","first-page":"CD011129","article-title":"Early palliative care for adults with advanced cancer","volume":"6","author":"M W Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref460","first-page":"660","article-title":"[Integration of palliative care into intensive care: Systematic review]","volume":"66","author":"K Adler","year":"2017","journal-title":"Anaesthesist"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1478951513001338","article-title":"Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome","volume":"12","author":"K M Dalgaard","year":"2014","journal-title":"Palliat Support Care"},{"key":"ref462","first-page":"99","article-title":"A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses","volume":"4","author":"M P Davis","year":"2015","journal-title":"Ann Palliat Med"},{"key":"ref463","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1634\/theoncologist.2014-0312","article-title":"Integration of oncology and palliative care: a systematic review","volume":"20","author":"D Hui","year":"2015","journal-title":"Oncologist"},{"key":"ref464","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1634\/theoncologist.2016-0006","article-title":"Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review","volume":"21","author":"D Hui","year":"2016","journal-title":"Oncologist"},{"key":"ref465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574887110666151014141650","article-title":"Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature","volume":"11","author":"D Tassinari","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"ref466","first-page":"501","article-title":"[Physical complaints, stress and quality of life of oncologic patients Effects and patient assessment in inpatient rehabilitation]","volume":"91","author":"U G\u00e4rtner","year":"1996","journal-title":"Med Klin (Munich)"},{"key":"ref468","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1634\/theoncologist.2015-0015","article-title":"Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study","volume":"20","author":"J Hamano","year":"2015","journal-title":"Oncologist"},{"key":"ref469","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0269216314526273","article-title":"The \u201csurprise\u201d question in advanced cancer patients: A prospective study among general practitioners","volume":"28","author":"M Moroni","year":"2014","journal-title":"Palliat Med"},{"key":"ref470","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0269216311401949","article-title":"Using the \u201csurprise question\u201d can identify people with advanced heart failure and COPD who would benefit from a palliative care approach","volume":"25","author":"S Murray","year":"2011","journal-title":"Palliat Med"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/jpm.2010.0018","article-title":"Prognostic significance of the \u201csurprise\u201d question in cancer patients","volume":"13","author":"A H Moss","year":"2010","journal-title":"J Palliat Med"},{"key":"ref472","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis","volume":"68","author":"A E Kremer","year":"2008","journal-title":"Drugs"},{"key":"ref473","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/ddg.13304_g","article-title":"S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus \u2013 Update \u2013 Kurzversion","volume":"15","author":"S Stander","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref474","first-page":"456","article-title":"Pathogenesis of pruritus","volume":"9","author":"S Stander","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref475","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"L Bachs","year":"1989","journal-title":"Lancet"},{"key":"ref476","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin Results of a double-blind, crossover, randomized trial","volume":"94","author":"C N Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"ref477","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"R Terg","year":"2002","journal-title":"J Hepatol"},{"key":"ref478","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"N V Bergasa","year":"1992","journal-title":"Gastroenterology"},{"key":"ref479","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"M J Mayo","year":"2007","journal-title":"Hepatology"},{"key":"ref480","first-page":"691","article-title":"Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"K D Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"J A Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref482","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1478-3231.2004.0996.x","article-title":"Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy A 12-year experience","volume":"25","author":"R Zapata","year":"2005","journal-title":"Liver Int"},{"key":"ref483","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/j.lpm.2009.09.027","article-title":"Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation","volume":"39","author":"M Lemyze","year":"2010","journal-title":"Presse Med"},{"key":"ref484","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/lt.20088?download=true","article-title":"Aerobic capacity is associated with 100-day outcome after hepatic transplantation","volume":"10","author":"S K Epstein","year":"2004","journal-title":"Liver Transpl"},{"key":"ref485","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00421-007-0435-6","article-title":"Physical fitness, fatigue, and quality of life after liver transplantation","volume":"100","author":"B T van Ginneken","year":"2007","journal-title":"Eur J Appl Physiol"},{"key":"ref486","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/lt.20684?download=true","article-title":"Fatigue is a major problem after liver transplantation","volume":"12","author":"R van den Berg-Emons","year":"2006","journal-title":"Liver Transpl"},{"key":"ref487","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3109\/09638288.2010.482174","article-title":"Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients","volume":"32","author":"B T van Ginneken","year":"2010","journal-title":"Disabil Rehabil"},{"key":"ref488","first-page":"55","article-title":"[Changes in quality of life in oncological patients in the course of an inpatient after-care program]","volume":"30","author":"G Schwibbe","year":"1991","journal-title":"Rehabilitation (Stuttg)"},{"key":"ref489","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/pon.3146?download=true","article-title":"Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping","volume":"22","author":"S Y Fan","year":"2013","journal-title":"Psychooncology"},{"key":"ref490","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cgh.2010.03.008","article-title":"Health-related quality of life in patients with hepatocellular carcinoma: a systematic review","volume":"8","author":"S Y Fan","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3748\/wjg.v18.i21.2689","article-title":"Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma","volume":"18","author":"C X Qiao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"ref492","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2006.06.4592","article-title":"Depression, immunity, and survival in patients with hepatobiliary carcinoma","volume":"25","author":"J L Steel","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref493","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jad.2018.12.085","article-title":"Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma","volume":"246","author":"H H Lee","year":"2019","journal-title":"J Affect Disord"},{"key":"ref494","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/NCC.0b013e3181ac6248","article-title":"The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma","volume":"32","author":"T W Huang","year":"2009","journal-title":"Cancer Nurs"},{"key":"ref495","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pon.3705?download=true","article-title":"Suicide in cancer patients within the first year of diagnosis","volume":"24","author":"M H Ahn","year":"2015","journal-title":"Psychooncology"},{"key":"ref496","first-page":"65","article-title":"Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study","volume":"19","author":"C C Chiu","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref497","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1634\/theoncologist.2011-0368","article-title":"Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study","volume":"17","author":"S C Shun","year":"2012","journal-title":"Oncologist"},{"key":"ref498","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/NCC.0000000000000403","article-title":"The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home","volume":"40","author":"S C Shun","year":"2017","journal-title":"Cancer Nurs"},{"key":"ref499","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3748\/wjg.14.931","article-title":"Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia","volume":"14","author":"Z X Wang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref500","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/%28SICI%291097-0142%2820000101%2988%3A1%3C226%3A%3AAID-CNCR30%3E3.0.CO%3B2-P?download=true","article-title":"The unmet supportive care needs of patients with cancer Supportive Care Review Group","volume":"88","author":"R Sanson-Fisher","year":"2000","journal-title":"Cancer"},{"key":"ref501","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-004-0727-x","article-title":"Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study","volume":"13","author":"U R Kleeberg","year":"2005","journal-title":"Support Care Cancer"},{"key":"ref502","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(03)15392-5","article-title":"Communicating sad, bad, and difficult news in medicine","volume":"363","author":"L Fallowfield","year":"2004","journal-title":"Lancet"},{"key":"ref503","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0738-3991(99)00108-1","article-title":"Doctor-patient communication and cancer patients\u2019 quality of life and satisfaction","volume":"41","author":"L M Ong","year":"2000","journal-title":"Patient Educ Couns"},{"key":"ref504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.cco.0000167735.26454.79","article-title":"Communication in palliative care: a review of recent literature","volume":"17","author":"H de Haes","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"ref505","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/cncr.23710?download=true","article-title":"A randomized study assessing the efficacy of communication skill training on patients\u2019 psychologic distress and coping: nurses\u2019 communication with patients just after being diagnosed with cancer","volume":"113","author":"S Fukui","year":"2008","journal-title":"Cancer"},{"key":"ref506","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2003.08.031","article-title":"How to optimize physicians\u2019 communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops","volume":"21","author":"D Razavi","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref507","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/pon.1262?download=true","article-title":"Factors that influence cancer patients\u2019 and relatives\u2019 anxiety following a three-person medical consultation: impact of a communication skills training program for physicians","volume":"17","author":"A Lienard","year":"2008","journal-title":"Psychooncology"},{"key":"ref508","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1369-7625.2006.00401.x","article-title":"Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision","volume":"9","author":"A Edwards","year":"2006","journal-title":"Health Expect"},{"key":"ref509","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pec.2009.06.009","article-title":"Shared decision making coding systems: how do they compare in the oncology context?","volume":"78","author":"P Butow","year":"2010","journal-title":"Patient Educ Couns"},{"key":"ref510","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1399-0012.2011.01480.x?download=true","article-title":"Are informed consent forms for organ transplantation and donation too difficult to read?","volume":"26","author":"E J Gordon","year":"2012","journal-title":"Clin Transplant"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/lt.22437","article-title":"Patient decision making about organ quality in liver transplantation","volume":"17","author":"M L Volk","year":"2011","journal-title":"Liver Transpl"},{"key":"ref512","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/lt.22355?download=true","article-title":"Patients\u2019 expectations and success criteria for liver transplantation","volume":"17","author":"J R Rodrigue","year":"2011","journal-title":"Liver Transpl"},{"key":"ref513","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1749-6632.1997.tb48095.x?download=true","article-title":"Communication with cancer patients in culturally diverse societies","volume":"809","author":"P N Butow","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"ref514","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/%28SICI%291099-1611%28200003\/04%299%3A2%3C147%3A%3AAID-PON443%3E3.0.CO%3B2-X?download=true","article-title":"Communication styles in the cancer consultation: preferences for a patient-centred approach","volume":"9","author":"S M Dowsett","year":"2000","journal-title":"Psychooncology"},{"key":"ref515","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pec.2005.11.003","article-title":"Making communication research matter: what do patients notice, what do patients want, and what do patients need?","volume":"60","author":"R M Epstein","year":"2006","journal-title":"Patient Educ Couns"},{"key":"ref516","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6600798","article-title":"Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease","volume":"88","author":"R Zachariae","year":"2003","journal-title":"Br J Cancer"},{"key":"ref517","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jpainsymman.2004.08.011","article-title":"Impact of physician sitting versus standing during inpatient oncology consultations: patients\u2019 preference and perception of compassion and duration A randomized controlled trial","volume":"29","author":"F Strasser","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"ref518","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1999.17.1.371","article-title":"Can 40 seconds of compassion reduce patient anxiety?","volume":"17","author":"L A Fogarty","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref519","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ijc.25362?download=true","article-title":"Risk of cancer in a large cohort of US veterans with diabetes","volume":"128","author":"E A Atchison","year":"2011","journal-title":"Int J Cancer"},{"key":"ref520","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1478-3231.2011.02614.x?download=true","article-title":"Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort","volume":"32","author":"M B de Valle","year":"2012","journal-title":"Liver Int"},{"key":"ref521","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.22606?download=true","article-title":"Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of US veterans","volume":"49","author":"H B El-Serag","year":"2009","journal-title":"Hepatology"},{"key":"ref522","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.18632\/oncotarget.20141","article-title":"Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis","volume":"8","author":"Y Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref523","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CEJ.0b013e3283481d89","article-title":"Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis","volume":"21","author":"W Jing","year":"2012","journal-title":"Eur J Cancer Prev"},{"key":"ref524","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"W C Palmer","year":"2012","journal-title":"J Hepatol"},{"key":"ref525","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12876-017-0696-4","article-title":"Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis","volume":"17","author":"N Wongjarupong","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"ref526","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1440-1746.2008.05689.x?download=true","article-title":"Long-term follow up of gallbladder polyps","volume":"24","author":"J Y Park","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"ref527","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/apt.12655?download=true","article-title":"Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer","volume":"39","author":"V Nagaraja","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref528","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"N Razumilava","year":"2014","journal-title":"Lancet"},{"key":"ref529","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2013 evolving concepts and therapeutic strategies","volume":"15","author":"S Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref530","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"J W Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"S Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"ref532","first-page":"605","article-title":"Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis","volume":"19","author":"S Kamsa-ard","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref533","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(15)60313-0","article-title":"Clonorchiasis","volume":"387","author":"M B Qian","year":"2016","journal-title":"Lancet"},{"key":"ref534","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2214-109X(16)30301-1","article-title":"Global burden of cancers attributable to liver flukes","volume":"5","author":"M B Qian","year":"2017","journal-title":"Lancet Glob Health"},{"key":"ref535","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5009\/gnl18339","article-title":"Natural Course and Risk of Cholangiocarcinoma in Patients with Recurrent Pyogenic Cholangitis: A Retrospective Cohort Study","volume":"13","author":"M S You","year":"2019","journal-title":"Gut Liver"},{"key":"ref536","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/bjs.10798","article-title":"Meta-analysis of risk of developing malignancy in congenital choledochal malformation","volume":"105","author":"A Ten Hove","year":"2018","journal-title":"Br J Surg"},{"key":"ref537","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.3748\/wjg.v26.i31.4718","article-title":"Risk of malignancy in Caroli disease and syndrome: A systematic review","volume":"26","author":"R Fahrner","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref538","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"M M Claessen","year":"2009","journal-title":"J Hepatol"},{"key":"ref539","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351?download=true","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"G L Tyson","year":"2011","journal-title":"Hepatology"},{"key":"ref540","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/jnci\/djz103","article-title":"Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies","volume":"111","author":"E E McGee","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"O Clements","year":"2020","journal-title":"J Hepatol"},{"key":"ref542","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/cco.2019.08.13","article-title":"Gallbladder cancer: epidemiology and genetic risk associations","volume":"8","author":"M A Schmidt","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"ref543","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"P Rawla","year":"2019","journal-title":"Clin Exp Hepatol"},{"issue":"S 01","key":"ref544","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1055\/s-0029-1245265","article-title":"[Gallbladder polyps: prevalence and risk factors]","volume":"32","author":"W Kratzer","year":"2011","journal-title":"Ultraschall Med"},{"key":"ref545","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s11605-013-2170-0","article-title":"Porcelain gallbladder: a benign process or concern for malignancy?","volume":"17","author":"T Schnelldorfer","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"ref546","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jamcollsurg.2017.11.026","article-title":"Porcelain Gallbladder: Is Observation a Safe Option in Select Populations?","volume":"226","author":"H DesJardins","year":"2018","journal-title":"J Am Coll Surg"},{"key":"ref547","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/PAS.0b013e31822179cc","article-title":"Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas","volume":"35","author":"S Patel","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"ref548","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1055\/a-0644-2972","article-title":"[Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) \u2013 AWMF Registry 021\/008]","volume":"56","author":"C Gutt","year":"2018","journal-title":"Z Gastroenterol"},{"key":"ref549","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ajg.2011.361","article-title":"Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis","volume":"107","author":"J E Eaton","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref550","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","article-title":"[Practice guideline autoimmune liver diseases \u2013 AWMF-Reg No 021-27]","volume":"55","year":"2017","journal-title":"Z Gastroenterol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1007\/s00330-017-4742-y","article-title":"Management and follow-up of gallbladder polyps: Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery\u200a\u2013\u200aEuropean Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE)","volume":"27","author":"R Wiles","year":"2017","journal-title":"Eur Radiol"},{"key":"ref552","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3748\/wjg.v25.i6.659","article-title":"Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies","volume":"25","author":"B M Fung","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref553","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/hep.22441?download=true","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"P Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"ref554","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/1751-2980.12311","article-title":"Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy","volume":"17","author":"I Naitoh","year":"2016","journal-title":"J Dig Dis"},{"key":"ref555","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis","volume":"81","author":"U Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"ref556","first-page":"265","volume-title":"Tumors of the gallbladder and extrahepatic bile ducts","author":"D SLA Klimstra","year":"2019"},{"key":"ref557","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","article-title":"Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity","volume":"66","author":"A Moeini","year":"2017","journal-title":"J Hepatol"},{"key":"ref558","first-page":"499","volume-title":"Other tumours of the digestive system","author":"V SP Paradis","year":"2019"},{"key":"ref559","volume-title":"C W. TNM-Klassifikation maligner Tumoren (8 Auflage, korrigierter Nachdruck)","year":"2020"},{"key":"ref560","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-79410-0","volume-title":"Organspezifische Tumordokumentation \u2013 Prinzipien und Verschl\u00fcsselungsanweisungen f\u00fcr Klinik und Praxis. Online-version: deutsche Krebsgesellschaft","author":"G HP Wagner","year":"1995"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-015-1475-7","article-title":"Cohort profile: cholangiocarcinoma screening and care program (CASCAP)","volume":"15","author":"N Khuntikeo","year":"2015","journal-title":"BMC Cancer"},{"key":"ref562","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00261-012-9854-x","article-title":"Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis","volume":"38","author":"R Li","year":"2013","journal-title":"Abdom Imaging"},{"key":"ref563","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1259\/bjr\/21653786","article-title":"Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination","volume":"85","author":"H X Xu","year":"2012","journal-title":"Br J Radiol"},{"key":"ref564","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0034-1399147","article-title":"CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients \u2013 early or late washout matters: a subanalysis of the DEGUM multicenter trial","volume":"36","author":"D Wildner","year":"2015","journal-title":"Ultraschall Med"},{"key":"ref565","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1148\/radiology.201.1.8816536","article-title":"Portal vein evaluation with US: comparison to angiography combined with CT arterial portography","volume":"201","author":"A M Bach","year":"1996","journal-title":"Radiology"},{"key":"ref566","first-page":"CD012233","article-title":"Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps","volume":"8","author":"S Z Wennmacker","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref567","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/00004728-199909000-00004","article-title":"Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI","volume":"23","author":"Y Zhang","year":"1999","journal-title":"J Comput Assist Tomogr"},{"key":"ref568","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00261-012-9964-5","article-title":"Routine use of precontrast and delayed acquisitions in abdominal CT: time for change","volume":"38","author":"P T Johnson","year":"2013","journal-title":"Abdom Imaging"},{"key":"ref569","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/hbsn.2016.12.10","article-title":"Multimodality imaging of intrahepatic cholangiocarcinoma","volume":"6","author":"K Fabrega-Foster","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref570","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s002610000079","article-title":"Intrahepatic peripheral cholangiocarcinoma: CT evaluation","volume":"25","author":"C Valls","year":"2000","journal-title":"Abdom Imaging"},{"key":"ref571","doi-asserted-by":"publisher","first-page":"W205","DOI":"10.2214\/Am J Roentgenol.10.4937","article-title":"Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma","volume":"196","author":"J H Kim","year":"2011","journal-title":"Am J Roentgenol"},{"key":"ref572","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"J Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"ref573","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jmri.24810","article-title":"MRI of cholangiocarcinoma","volume":"42","author":"K S Jhaveri","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"ref574","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jmri.1880050210","article-title":"Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study","volume":"5","author":"T Murakami","year":"1995","journal-title":"J Magn Reson Imaging"},{"key":"ref575","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2214\/ajr.158.1.1309221","article-title":"Intrahepatic cholangiocarcinoma: MR appearance","volume":"158","author":"J Hamrick-Turner","year":"1992","journal-title":"Am J Roentgenol"},{"key":"ref576","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2214\/ajr.161.2.8392787","article-title":"Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging","volume":"161","author":"Z M Fan","year":"1993","journal-title":"Am J Roentgenol"},{"key":"ref578","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1148\/rg.293085729","article-title":"Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation","volume":"29","author":"Y E Chung","year":"2009","journal-title":"Radiographics"},{"key":"ref579","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00261-012-9943-x","article-title":"Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma","volume":"38","author":"H J Park","year":"2013","journal-title":"Abdom Imaging"},{"key":"ref580","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ejrad.2015.05.003","article-title":"Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging","volume":"84","author":"H E Fattach","year":"2015","journal-title":"Eur J Radiol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/gastro\/gou057","article-title":"Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis","volume":"3","author":"U Navaneethan","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref582","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00261-016-0635-9","article-title":"Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?","volume":"41","author":"J K Pahade","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"ref583","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00330-014-3097-x","article-title":"The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures","volume":"24","author":"H J Park","year":"2014","journal-title":"Eur Radiol"},{"key":"ref584","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.2016151781","article-title":"Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker","volume":"281","author":"J Lee","year":"2016","journal-title":"Radiology"},{"key":"ref585","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"C Rupp","year":"2019","journal-title":"Gut"},{"key":"ref586","first-page":"497942","article-title":"Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"2015","author":"H Zhang","year":"2015","journal-title":"Biomed Res Int"},{"key":"ref587","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"(18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis","volume":"71","author":"A Lamarca","year":"2019","journal-title":"J Hepatol"},{"key":"ref588","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12885-015-1039-x","article-title":"Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity","volume":"15","author":"S T Feng","year":"2015","journal-title":"BMC Cancer"},{"key":"ref589","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RCT.0b013e3182706562","article-title":"Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging","volume":"36","author":"S H Kim","year":"2012","journal-title":"J Comput Assist Tomogr"},{"issue":"01","key":"ref590","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis","volume":"71","author":"A Lamarca","year":"2019","journal-title":"J Hepatol"},{"key":"ref591","doi-asserted-by":"publisher","first-page":"20210008","DOI":"10.1259\/bjro.20210008","article-title":"Impact of 18F-FDG-PET\/CT on Clinical Management in Patients with Cholangiocellular Carcinoma","volume":"3","author":"L S Kiefer","year":"2021","journal-title":"BJR|Open"},{"key":"ref592","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/2303-9027.193597","article-title":"Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis","volume":"7","author":"D TH De Moura","year":"2018","journal-title":"Endosc Ultrasound"},{"key":"ref593","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1477-2574.2011.00298.x","article-title":"Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination","volume":"13","author":"J K Heimbach","year":"2011","journal-title":"HPB (Oxford)"},{"key":"ref594","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0033-1344760","article-title":"Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients","volume":"45","author":"A H El Chafic","year":"2013","journal-title":"Endoscopy"},{"key":"ref595","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.gie.2016.04.039","article-title":"ERCP tissue sampling","volume":"84","author":"P Korc","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"ref596","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gie.2005.08.039","article-title":"Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study","volume":"63","author":"E L Fogel","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"ref597","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4253\/wjge.v6.i7.312","article-title":"Improved endoscopic retrograde cholangiopancreatography brush increases diagnostic yield of malignant biliary strictures","volume":"6","author":"F K Shieh","year":"2014","journal-title":"World J Gastrointest Endosc"},{"key":"ref598","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1055\/s-1999-73","article-title":"Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography","volume":"31","author":"B Glasbrenner","year":"1999","journal-title":"Endoscopy"},{"key":"ref599","first-page":"254","article-title":"Brush cytology of ductal strictures during ERCP","volume":"63","author":"E Macken","year":"2000","journal-title":"Acta Gastroenterol Belg"},{"key":"ref600","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.40.5.671","article-title":"A prospective evaluation of cytology from biliary strictures","volume":"40","author":"J C Mansfield","year":"1997","journal-title":"Gut"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.gie.2013.09.015","article-title":"Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"79","author":"G Trikudanathan","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"ref602","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.gie.2011.09.020","article-title":"Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study","volume":"75","author":"P V Draganov","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"ref603","first-page":"465","article-title":"Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology","volume":"91","author":"M Sugiyama","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"ref604","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0016-5107(00)70435-4","article-title":"Triple-tissue sampling at ERCP in malignant biliary obstruction","volume":"51","author":"J Jailwala","year":"2000","journal-title":"Gastrointest Endosc"},{"key":"ref605","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cgh.2012.05.025","article-title":"Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures","volume":"10","author":"D J Hartman","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref606","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0016-5107(95)70004-8","article-title":"Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study","volume":"42","author":"V Pugliese","year":"1995","journal-title":"Gastrointest Endosc"},{"key":"ref607","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/j.1440-1746.2007.05037.x","article-title":"Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures","volume":"22","author":"Y Kitajima","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"ref608","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.gie.2015.04.030","article-title":"Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review","volume":"82","author":"U Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"ref609","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.11.025","article-title":"Digital single-operator peroral cholangioscopy-guided biopsy versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized multicenter trial (with video)","author":"C Gerges","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"ref610","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"49","author":"L Aabakken","year":"2017","journal-title":"Endoscopy"},{"key":"ref611","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11605-017-3426-x","article-title":"Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System","volume":"22","author":"F Bagante","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"ref612","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00268-017-4453-1","article-title":"Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes","volume":"42","author":"F Bagante","year":"2018","journal-title":"World J Surg"},{"key":"ref613","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/bjs.10556?download=true","article-title":"Surgical resection for Bismuth type IV perihilar cholangiocarcinoma","volume":"105","author":"T Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"ref614","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","article-title":"Intrahepatic Cholangiocarcinoma","volume":"28","author":"R El-Diwany","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"ref615","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jamcollsurg.2008.10.017","article-title":"Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients","volume":"208","author":"H Lang","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"ref616","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1245\/s10434-019-07968-7","article-title":"The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort","volume":"27","author":"A A Schnitzbauer","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"ref617","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s11605-017-3499-6","article-title":"Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy","volume":"21","author":"X F Zhang","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"ref618","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijsu.2019.05.006","article-title":"Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study","volume":"67","author":"F Bartsch","year":"2019","journal-title":"Int J Surg"},{"key":"ref619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.suronc.2019.07.002","article-title":"Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches","volume":"33","author":"T Mizuno","year":"2020","journal-title":"Surg Oncol"},{"key":"ref620","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00423-018-1649-2","article-title":"Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience","volume":"403","author":"F Rassam","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"J N Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref622","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/bjs.10641?download=true","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"B Le Roy","year":"2018","journal-title":"Br J Surg"},{"key":"ref623","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12957-020-01915-7","article-title":"Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases","volume":"18","author":"Y Chang","year":"2020","journal-title":"World J Surg Oncol"},{"key":"ref624","doi-asserted-by":"crossref","first-page":"e1496","DOI":"10.1590\/0102-672020190001e1496","article-title":"BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA","volume":"33","author":"F JF Coimbra","year":"2020","journal-title":"Arq Bras Cir Dig"},{"key":"ref625","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/jso.20535?download=true","article-title":"Surgical strategies in patients with gallbladder cancer: nihilism to optimism","volume":"93","author":"S S Sikora","year":"2006","journal-title":"J Surg Oncol"},{"key":"ref626","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/bjs.11035?download=true","article-title":"Systematic review of management of incidental gallbladder cancer after cholecystectomy","volume":"106","author":"K S\u00f8reide","year":"2019","journal-title":"Br J Surg"},{"key":"ref627","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","article-title":"NCCN clinical practice guidelines in oncology: hepatobiliary cancers","volume":"7","author":"A B Benson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref628","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12885-019-6507-2","article-title":"Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation","volume":"20","author":"K Yuza","year":"2020","journal-title":"BMC Cancer"},{"key":"ref629","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1245\/s10434-014-3527-7","article-title":"Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea","volume":"21","author":"S E Lee","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref630","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00268-018-04876-x","article-title":"Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma","volume":"43","author":"F Bartsch","year":"2019","journal-title":"World J Surg"},{"key":"ref631","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1245\/s10434-015-4642-9","article-title":"Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection","volume":"23","author":"G Spolverato","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"ref632","doi-asserted-by":"crossref","first-page":"8732521","DOI":"10.1155\/2016\/8732521","article-title":"Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma","volume":"2016","author":"R Seidensticker","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"ref633","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/02656736.2019.1571247?needAccess=true","article-title":"Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results","volume":"36","author":"C Xu","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"ref634","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1245\/s10434-013-3035-1","article-title":"Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma","volume":"20","author":"S J Zhang","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref635","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jso.23605","article-title":"Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis","volume":"110","author":"N Amini","year":"2014","journal-title":"J Surg Oncol"},{"key":"ref636","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.clinimag.2014.01.013","article-title":"Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome","volume":"38","author":"S R Butros","year":"2014","journal-title":"Clin Imaging"},{"key":"ref637","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jvir.2012.01.081","article-title":"Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma","volume":"23","author":"Y Fu","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"ref638","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jvir.2015.02.024","article-title":"Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"26","author":"K Han","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"ref639","doi-asserted-by":"crossref","first-page":"536","DOI":"10.21037\/jgo.2018.02.04","article-title":"Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis","volume":"9","author":"A R Kolarich","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"ref640","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s00261-018-1656-3","article-title":"Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression","volume":"43","author":"E A Takahashi","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.ejrad.2010.09.019","article-title":"Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection","volume":"80","author":"J H Kim","year":"2011","journal-title":"Eur J Radiol"},{"key":"ref642","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/lt.24955","article-title":"Current status of liver transplantation for cholangiocarcinoma","volume":"24","author":"N Goldaracena","year":"2018","journal-title":"Liver Transpl"},{"key":"ref643","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/TP.0000000000000286","article-title":"Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation","volume":"99","author":"M E Facciuto","year":"2015","journal-title":"Transplantation"},{"key":"ref644","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hpb.2015.10.001","article-title":"Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database","volume":"18","author":"V Vilchez","year":"2016","journal-title":"HPB (Oxford)"},{"key":"ref645","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/SLA.0000000000000494","article-title":"Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study","volume":"259","author":"G Sapisochin","year":"2014","journal-title":"Ann Surg"},{"key":"ref646","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment","volume":"64","author":"G Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref647","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"K E Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref648","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11605-007-0335-4","article-title":"Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period","volume":"12","author":"N S Becker","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"ref649","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Murad S Darwish","year":"2012","journal-title":"Gastroenterology"},{"key":"ref650","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/13651820801992542","article-title":"Surgery for cholangiocarcinoma: the role of liver transplantation","volume":"10","author":"C B Rosen","year":"2008","journal-title":"HPB (Oxford)"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/hep.15.30","article-title":"Liver transplantation in the management of perihilar cholangiocarcinoma","volume":"2","author":"A F Gulamhusein","year":"2015","journal-title":"Hepat Oncol"},{"key":"ref652","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000002574","article-title":"Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease","volume":"267","author":"C G Ethun","year":"2018","journal-title":"Ann Surg"},{"key":"ref653","doi-asserted-by":"crossref","first-page":"e0156127","DOI":"10.1371\/journal.pone.0156127","article-title":"Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival","volume":"11","author":"H T Mantel","year":"2016","journal-title":"PLoS One"},{"key":"ref654","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"S M Weber","year":"2015","journal-title":"HPB (Oxford)"},{"key":"ref655","volume-title":"NCCN Guidelines\u00ae for Hepatobiliary Cancers Version 3","year":"2019"},{"key":"ref656","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jvir.2013.03.019","article-title":"Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"24","author":"C E Ray","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"ref657","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000500894","article-title":"Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center","author":"C Koch","year":"2019","journal-title":"Digestion"},{"key":"ref658","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11605-007-0312-y","article-title":"Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience","volume":"12","author":"N J Gusani","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"ref659","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.23781","article-title":"Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma","volume":"111","author":"L M Boehm","year":"2015","journal-title":"J Surg Oncol"},{"key":"ref660","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/cncr.25625","article-title":"Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study","volume":"117","author":"M V Kiefer","year":"2011","journal-title":"Cancer"},{"key":"ref661","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ijc.26407","article-title":"Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success","volume":"131","author":"T J Vogl","year":"2012","journal-title":"Int J Cancer"},{"key":"ref662","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/liv.13382","article-title":"Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study","volume":"37","author":"A Cucchetti","year":"2017","journal-title":"Liver Int"},{"key":"ref663","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","article-title":"Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study","volume":"29","author":"A Gangi","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"ref664","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00259-018-3990-7","article-title":"A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and (90)Y-loaded glass microsphere selective internal radiation therapy","volume":"45","author":"V Manceau","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref665","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","article-title":"Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Na\u00efve Patients","volume":"41","author":"P Reimer","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref666","first-page":"570","article-title":"Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review","volume":"6","author":"L Yang","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"ref667","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.2147\/OTT.S202875","article-title":"A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma","volume":"12","author":"Y Zhen","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"05","key":"ref668","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis","volume":"44","author":"C Mosconi","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref669","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","article-title":"Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis","volume":"20","author":"O Hyder","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref670","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","article-title":"Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival","volume":"29","author":"S Marquardt","year":"2019","journal-title":"Eur Radiol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"J Edeline","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref672","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824?download=true","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"I T Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"ref673","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"D P Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"ref674","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jcm8040458","article-title":"Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma","volume":"8","author":"K M Wronka","year":"2019","journal-title":"J Clin Med"},{"key":"ref675","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jvir.2016.12.1218","article-title":"Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage?","volume":"28","author":"A Al Mahjoub","year":"2017","journal-title":"A Meta-Analysis. J Vasc Interv Radiol"},{"key":"ref676","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.hpb.2016.03.002","article-title":"Percutaneous vs endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma \u2013 a systematic review and meta-analysis","volume":"18","author":"A Hameed","year":"2016","journal-title":"HPB (Oxford)"},{"key":"ref677","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2468-1253(18)30234-6","article-title":"Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial","volume":"3","author":"R JS Coelen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref678","doi-asserted-by":"publisher","first-page":"E203","DOI":"10.1055\/a-0990-9114","article-title":"Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma","volume":"8","author":"Y Ba","year":"2020","journal-title":"Endosc Int Open"},{"key":"ref679","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jhbp.640?download=true","article-title":"Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma","volume":"26","author":"T Maeda","year":"2019","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref680","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jgh.14050?download=true","article-title":"Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study","volume":"33","author":"Y Nakai","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.surg.2016.08.008","article-title":"Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma","volume":"161","author":"K Komaya","year":"2017","journal-title":"Surgery"},{"key":"ref682","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5009\/gnl14243","article-title":"A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage","volume":"9","author":"K M Kim","year":"2015","journal-title":"Gut Liver"},{"key":"ref683","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1477-2574.2009.00090.x","article-title":"Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma","volume":"11","author":"T J Kennedy","year":"2009","journal-title":"HPB (Oxford)"},{"key":"ref684","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00464-019-06813-y","article-title":"Preoperative biliary drainage of the hepatic lobe to be resected does not affect liver hypertrophy after percutaneous transhepatic portal vein embolization","volume":"34","author":"S Miura","year":"2020","journal-title":"Surg Endosc"},{"key":"ref685","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mge.2001.111388","article-title":"Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors","volume":"53","author":"R E Hintze","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"ref686","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5107(02)70356-8","article-title":"Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life","volume":"56","author":"N S Abraham","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"ref687","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gie.2008.04.005","article-title":"Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach","volume":"69","author":"W H Paik","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"ref688","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.cgh.2008.03.028","article-title":"Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment","volume":"6","author":"S S Saluja","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref689","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0009-9260(97)80275-9","article-title":"Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction","volume":"52","author":"W Schima","year":"1997","journal-title":"Clin Radiol"},{"key":"ref690","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00270-011-0103-4","article-title":"British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR)","volume":"35","author":"R Uberoi","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(94)90455-3","article-title":"Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction","volume":"344","author":"A C Smith","year":"1994","journal-title":"Lancet"},{"key":"ref692","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(87)92733-4","article-title":"Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice","volume":"2","author":"A G Speer","year":"1987","journal-title":"Lancet"},{"key":"ref693","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ajg.2016.512","article-title":"Plastic vs Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses","volume":"112","author":"M A Almadi","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref694","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.gie.2019.03.011","article-title":"Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture","volume":"90","author":"T H Lee","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"ref695","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1007\/s00464-016-4913-y","article-title":"Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage: predictors of successful outcome in patients who fail endoscopic retrograde cholangiopancreatography","volume":"30","author":"R Z Sharaiha","year":"2016","journal-title":"Surg Endosc"},{"key":"ref696","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41395-018-0122-8","article-title":"EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial","volume":"113","author":"W H Paik","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref697","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gie.2018.03.012","article-title":"Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos)","volume":"88","author":"J Y Bang","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"ref698","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1055\/a-0659-9864","article-title":"Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline \u2013 Updated October 2017","volume":"50","author":"J M Dumonceau","year":"2018","journal-title":"Endoscopy"},{"key":"ref699","doi-asserted-by":"crossref","first-page":"4726078","DOI":"10.1155\/2016\/4726078","article-title":"Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review","volume":"2016","author":"H Moole","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref700","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/den.12320?download=true","article-title":"Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis","volume":"27","author":"X Q Zhao","year":"2015","journal-title":"Dig Endosc"},{"key":"ref701","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/00365529850172142?needAccess=true","article-title":"Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures","volume":"33","author":"P Born","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"ref702","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mge.2001.113381","article-title":"Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study","volume":"53","author":"G D De Palma","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"ref703","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0016-5107(98)70218-4","article-title":"Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage","volume":"47","author":"W H Chang","year":"1998","journal-title":"Gastrointest Endosc"},{"key":"ref704","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1499-3872(12)60150-7","article-title":"Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage","volume":"11","author":"M Bulajic","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref705","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mge.2002.125364","article-title":"Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents","volume":"56","author":"J L Cheng","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"ref706","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.gie.2010.06.040","article-title":"Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment","volume":"72","author":"A Vienne","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"ref707","doi-asserted-by":"crossref","first-page":"e033576","DOI":"10.1136\/bmjopen-2019-033576","article-title":"The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study","volume":"10","author":"J Rees","year":"2020","journal-title":"BMJ Open"},{"key":"ref708","doi-asserted-by":"crossref","first-page":"100212","DOI":"10.1016\/j.eclinm.2019.11.005","article-title":"Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction","volume":"18","author":"P R Harvey","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref709","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4253\/wjge.v6.i1.13","article-title":"Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction","volume":"6","author":"A O Tal","year":"2014","journal-title":"World J Gastrointest Endosc"},{"key":"ref710","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3748\/wjg.v23.i7.1278","article-title":"Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis","volume":"23","author":"H Moole","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1067\/mge.2001.119605","article-title":"Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer","volume":"54","author":"T Zoepf","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"ref712","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.gastro.2003.07.015","article-title":"Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study","volume":"125","author":"M E Ortner","year":"2003","journal-title":"Gastroenterology"},{"key":"ref713","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1572-0241.2005.00318.x","article-title":"Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy","volume":"100","author":"T Zoepf","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"ref714","first-page":"e000379","article-title":"PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer","volume":"3","author":"S P Pereira","year":"2018","journal-title":"ESMO Open"},{"key":"ref715","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/apt.15050?download=true","article-title":"Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma","volume":"49","author":"M A Gonzalez-Carmona","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref716","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5009\/gnl15175","article-title":"Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma","volume":"10","author":"R Wentrup","year":"2016","journal-title":"Gut Liver"},{"key":"ref717","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.gie.2014.02.1030","article-title":"ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma","volume":"80","author":"D S Strand","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"ref718","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/2050640616654037","article-title":"Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications","volume":"5","author":"W Dolak","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"ref719","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cgh.2007.12.004","article-title":"Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy","volume":"6","author":"M Kahaleh","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref720","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"E Ben-Josef","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"T B Brunner","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref722","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis","volume":"34","author":"R Tao","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref723","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","article-title":"Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review","volume":"195","author":"J Lee","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"ref724","doi-asserted-by":"crossref","first-page":"20180688","DOI":"10.1259\/bjr.20180688","article-title":"Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review","volume":"92","author":"R Frakulli","year":"2019","journal-title":"Br J Radiol"},{"key":"ref725","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"B M Barney","year":"2012","journal-title":"Radiat Oncol"},{"key":"ref726","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"R V Tse","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref727","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2016.07.020","article-title":"Stereotactic body radiotherapy for primary hepatic malignancies \u2013 Report of a phase I\/II institutional study","volume":"121","author":"A A Weiner","year":"2016","journal-title":"Radiother Oncol"},{"key":"ref728","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"N Kopek","year":"2010","journal-title":"Radiother Oncol"},{"key":"ref729","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00270-011-0249-0","article-title":"Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma","volume":"35","author":"D Schnapauff","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref730","first-page":"748","article-title":"The diagnosis and treatment of cholangiocarcinoma","volume":"111","author":"A Vogel","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"A M Horgan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"ref732","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"J Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref733","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1200\/JCO.2017.35.4_suppl.225","article-title":"Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial","volume":"35","author":"J Edeline","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref734","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","article-title":"Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies","volume":"164","author":"J Edeline","year":"2022","journal-title":"Eur J Cancer"},{"issue":"09","key":"ref735","first-page":"CD012814","article-title":"Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma","volume":"9","author":"V Luvira","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref736","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"D Y Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"ref737","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721?articleTools=true","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"J Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"ref738","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"R T Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref739","doi-asserted-by":"publisher","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"R T Shroff","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"ref740","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"T Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"J W Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"ref742","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2014.308","article-title":"Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review","volume":"47","author":"J O Park","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"07","key":"ref743","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cancers12071975","article-title":"Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial","volume":"12","author":"A Markussen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref744","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"J W Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"ref745","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"R Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref746","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"J W Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"ref747","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"E Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"01","key":"ref748","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33997 cases: diagnostic implications and pitfalls","volume":"33","author":"J P Solomon","year":"2019","journal-title":"Mod Pathol"},{"key":"ref749","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"J S Ross","year":"2014","journal-title":"Oncologist"},{"key":"ref750","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448?articleTools=true","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"A Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"ref751","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies \u2013 a role beyond breast cancer","volume":"17","author":"D Y Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"ref752","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21037\/jgo.2017.10.02","article-title":"Investigation of targetable predictive and prognostic markers in gallbladder carcinoma","volume":"9","author":"A Neyaz","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"ref753","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"M Javle","year":"2015","journal-title":"J Hematol Oncol"},{"key":"ref754","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1055\/s-0042-103498","article-title":"[Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]","volume":"54","author":"E Czink","year":"2016","journal-title":"Z Gastroenterol"},{"issue":"09","key":"ref755","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"M Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref756","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309?articleTools=true","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"D M Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref757","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"A KS Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref758","doi-asserted-by":"crossref","first-page":"E98","DOI":"10.21037\/jgo.2016.09.13","article-title":"Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review","volume":"7","author":"V Lavingia","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"ref759","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.21037\/jgo.2017.01.06","article-title":"Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion","volume":"8","author":"J Kocsis","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"ref760","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21037\/jgo.2019.03.05","article-title":"Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV","volume":"10","author":"T Bunyatov","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"09","key":"ref761","first-page":"1234","article-title":"Dabrafenib plus trametinib in patients with BRAF","volume":"21","author":"V Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref762","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"G Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref763","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"G K Abou-Alfa","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"10","key":"ref764","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"M Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref765","first-page":"228","article-title":"Futibatinib for","volume":"388","author":"L Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"ref766","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"V Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"ref767","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors","volume":"25","author":"R Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref768","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma","volume":"11","author":"J Cleary","year":"2021","journal-title":"Cancer Discov"},{"issue":"02","key":"ref769","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"M Katoh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref770","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","author":"A Marabelle","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"D T Le","year":"2017","journal-title":"Science"},{"key":"ref772","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596?articleTools=true","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"D T Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref773","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"B Goeppert","year":"2019","journal-title":"Br J Cancer"},{"issue":"09","key":"ref774","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"M Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"ref775","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"A Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref776","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"G K Abou-Alfa","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"05","key":"ref777","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"A Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref778","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"I Choi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref779","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin","volume":"119","author":"Y Zheng","year":"2018","journal-title":"Br J Cancer"},{"key":"ref780","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"C Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref781","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1016\/j.annonc.2022.07.081","article-title":"53MO Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116)","volume":"33","author":"A Vogel","year":"2022","journal-title":"Annals of Oncology"},{"issue":"03","key":"ref782","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaoncol.2020.6166","article-title":"Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)","volume":"7","author":"A Ramaswamy","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref784","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000342813","article-title":"Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation","volume":"86","author":"N Ashoori","year":"2012","journal-title":"Digestion"},{"key":"ref785","doi-asserted-by":"crossref","first-page":"e13255","DOI":"10.1111\/ctr.13255","article-title":"The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study","volume":"32","author":"A Boteon","year":"2018","journal-title":"Clin Transplant"},{"key":"ref786","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jvir.2018.11.037","article-title":"Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study","volume":"30","author":"P Habibollahi","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"ref787","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/hep.20688","article-title":"Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation","volume":"41","author":"D S Lu","year":"2005","journal-title":"Hepatology"},{"key":"ref788","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jvir.2009.10.038","article-title":"Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma","volume":"21","author":"A Nicolini","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"ref789","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jvir.2018.12.736","article-title":"Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort","volume":"30","author":"T Sandow","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"ref790","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14701\/ahbps.2018.22.1.27","article-title":"Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?","volume":"22","author":"C HN Tan","year":"2018","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"ref791","first-page":"638","article-title":"Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma","volume":"17","author":"J D Werner","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"ref792","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis","volume":"67","author":"G Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"ref793","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2011.05.020","article-title":"Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early\/early stage hepatocellular carcinoma","volume":"56","author":"J H Wang","year":"2012","journal-title":"J Hepatol"},{"key":"ref794","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1148\/radiol.11110817","article-title":"Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study","volume":"262","author":"Z W Peng","year":"2012","journal-title":"Radiology"},{"key":"ref795","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2012.11.009","article-title":"Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey","volume":"58","author":"K Hasegawa","year":"2013","journal-title":"J Hepatol"},{"key":"ref796","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jgh.12441","article-title":"Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma","volume":"29","author":"Y Fang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref797","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hpb.12446","article-title":"Surgical resection versus ablation for hepatocellular carcinoma \u2264 3 cm: a population-based analysis","volume":"17","author":"J T Miura","year":"2015","journal-title":"HPB (Oxford)"},{"key":"ref798","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S141968","article-title":"Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis","volume":"10","author":"M Zhang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref799","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/02656736.2016.1257824?needAccess=true","article-title":"Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients","volume":"33","author":"Q B Zhang","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"ref800","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SLA.0000000000001178","article-title":"Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma \u2264 2 \u200acm in a Propensity Score Model","volume":"263","author":"P H Liu","year":"2016","journal-title":"Ann Surg"},{"key":"ref801","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/liv.13670","article-title":"Impact of resection and ablation for single hypovascular hepatocellular carcinoma \u22642 cm analysed with propensity score weighting","volume":"38","author":"K Takayasu","year":"2018","journal-title":"Liver Int"},{"key":"ref802","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2010.08.018","article-title":"Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas","volume":"9","author":"H H Hung","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref803","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13651820510028846","article-title":"Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes","volume":"7","author":"M Ogihara","year":"2005","journal-title":"HPB (Oxford)"},{"key":"ref804","first-page":"801","article-title":"[Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]","volume":"86","author":"M D L\u00fc","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref805","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13651820701713758","article-title":"Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?","volume":"9","author":"L Lupo","year":"2007","journal-title":"HPB (Oxford)"},{"key":"ref806","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11605-008-0553-4","article-title":"Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma","volume":"12","author":"M Abu-Hilal","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"ref807","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jso.21745","article-title":"Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection","volume":"104","author":"H Tashiro","year":"2011","journal-title":"J Surg Oncol"},{"key":"ref808","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3348\/kjr.2013.14.4.626","article-title":"Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection","volume":"14","author":"J W Kim","year":"2013","journal-title":"Korean J Radiol"},{"key":"ref809","doi-asserted-by":"crossref","first-page":"e3754","DOI":"10.1097\/MD.0000000000003754","article-title":"Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study","volume":"95","author":"C Tang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref810","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12094-016-1611-0","article-title":"Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study","volume":"19","author":"A K Bholee","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.7150\/jca.19964","article-title":"Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study","volume":"8","author":"T Pan","year":"2017","journal-title":"J Cancer"},{"key":"ref812","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"R Zhang","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"ref813","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial","volume":"94","author":"D Y Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"ref814","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"G Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"ref815","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJM199505113321903?articleTools=true","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"ref816","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep.510270617?download=true","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"J Bruix","year":"1998","journal-title":"Hepatology"},{"key":"ref817","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial Groupe CHC","volume":"29","author":"G Pelletier","year":"1998","journal-title":"J Hepatol"},{"key":"ref818","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/1097-0142%2819950515%2975%3A10%3C2427%3A%3AAID-CNCR2820751007%3E3.0.CO%3B2-J?download=true","article-title":"Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma An Italian experience","volume":"75","author":"G F Stefanini","year":"1995","journal-title":"Cancer"},{"key":"ref819","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/1097-0142%2819940701%2974%3A1%3C16%3A%3AAID-CNCR2820740105%3E3.0.CO%3B2-V?download=true","article-title":"Transcatheter oily chemoembolization for hepatocellular carcinoma A 4-year study of 127 French patients","volume":"74","author":"J P Bronowicki","year":"1994","journal-title":"Cancer"},{"key":"ref820","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/j.1365-2036.2009.04016.x?download=true","article-title":"Transcatheter arterial chemoembolization vs chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis","volume":"29","author":"J H Kim","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref821","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s00270-007-9032-7","article-title":"Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma","volume":"30","author":"S Herber","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref822","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"G E Chung","year":"2011","journal-title":"Radiology"},{"key":"ref823","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis","volume":"16","author":"C S Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"ref824","first-page":"535","article-title":"Transcatheter arterial embolization for inoperable hepatocellular carcinoma","volume":"36","author":"M Okazaki","year":"1991","journal-title":"Jpn J Clin Radiol"},{"key":"ref825","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","article-title":"Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"22","author":"R Sacco","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"ref826","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000329602","article-title":"A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"34","author":"H van Malenstein","year":"2011","journal-title":"Onkologie"},{"key":"ref827","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jso.21522?download=true","article-title":"Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)","volume":"101","author":"R Dhanasekaran","year":"2010","journal-title":"J Surg Oncol"},{"key":"ref828","first-page":"246","article-title":"[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]","volume":"53","author":"M D Ferrer Puchol","year":"2011","journal-title":"Radiologia"},{"key":"ref829","doi-asserted-by":"crossref","first-page":"Cr189","DOI":"10.12659\/MSM.881714","article-title":"Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs TACE with cisplatin\/lipiodol (cTACE)","volume":"17","author":"P Wiggermann","year":"2011","journal-title":"Med Sci Monit"},{"key":"ref830","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","article-title":"Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma","volume":"57","author":"M J Song","year":"2012","journal-title":"J Hepatol"},{"key":"ref831","first-page":"496","article-title":"Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs","volume":"57","author":"J E Meg\u00edas Vericat","year":"2015","journal-title":"Radiologia"},{"key":"ref832","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12885-015-1480-x","article-title":"Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"15","author":"R Kloeckner","year":"2015","journal-title":"BMC Cancer"},{"key":"ref833","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jgh.13147?download=true","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"31","author":"A Facciorusso","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"ref834","first-page":"69","article-title":"Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma","volume":"8","author":"J Baur","year":"2016","journal-title":"Hepat Med"},{"key":"ref835","first-page":"813","article-title":"Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis","volume":"60","author":"S Gao","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"ref836","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jgh.12439?download=true","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"K Huang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref837","first-page":"3892","article-title":"Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis","volume":"7","author":"X Zhou","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"ref838","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/1751-2980.12380?download=true","article-title":"Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis","volume":"17","author":"J H Zou","year":"2016","journal-title":"J Dig Dis"},{"key":"ref839","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis","volume":"48","author":"A Facciorusso","year":"2016","journal-title":"Dig Liver Dis"},{"key":"ref840","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejso.2017.04.001","article-title":"Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis","volume":"43","author":"A Celotti","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref841","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s11605-018-3861-3","article-title":"Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma","volume":"22","author":"R Ramanathan","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"ref842","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5582\/bst.2017.01107","article-title":"Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center","volume":"11","author":"Y Cai","year":"2017","journal-title":"Biosci Trends"},{"key":"ref843","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/bjs.8950?download=true","article-title":"Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma","volume":"100","author":"O Farges","year":"2013","journal-title":"Br J Surg"},{"key":"ref844","doi-asserted-by":"crossref","first-page":"8731","DOI":"10.3748\/wjg.v19.i46.8731","article-title":"Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy","volume":"19","author":"J J Xiong","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref845","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12957-019-1656-y","article-title":"A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction","volume":"17","author":"L Wang","year":"2019","journal-title":"World J Surg Oncol"},{"key":"ref846","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00423-016-1427-y","article-title":"The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy","volume":"401","author":"Y Kishi","year":"2016","journal-title":"Langenbecks Arch Surg"},{"key":"ref847","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.gie.2012.02.048","article-title":"Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial","volume":"76","author":"A Sangchan","year":"2012","journal-title":"Gastrointest Endosc"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2189-6353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T20:01:28Z","timestamp":1764187288000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2189-6353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":844,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2189-6353","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}